Canna~Fangled Abstracts

Quality of Life and a Surveillant Endocannabinoid System

By October 28, 2021November 17th, 2021No Comments

Link to Publisher's site

Abstract

The endocannabinoid system (ECS) is an important brain modulatory network. ECS regulates brain homeostasis throughout development, from progenitor fate decision to neuro- and gliogenesis, synaptogenesis, brain plasticity and circuit repair, up to learning, memory, fear, protection, and death. It is a major player in the hypothalamic-peripheral system-adipose tissue in the regulation of food intake, energy storage, nutritional status, and adipose tissue mass, consequently affecting obesity. Loss of ECS control might affect mood disorders (anxiety, hyperactivity, psychosis, and depression), lead to drug abuse, and impact neurodegenerative (Alzheimer’s, Parkinson, Huntington, Multiple, and Amyotrophic Lateral Sclerosis) and neurodevelopmental (autism spectrum) disorders. Practice of regular physical and/or mind-body mindfulness and meditative activities have been shown to modulate endocannabinoid (eCB) levels, in addition to other players as brain-derived neurotrophic factor (BDNF). ECS is involved in pain, inflammation, metabolic and cardiovascular dysfunctions, general immune responses (asthma, allergy, and arthritis) and tumor expansion, both/either in the brain and/or in the periphery. The reason for such a vast impact is the fact that arachidonic acid, a precursor of eCBs, is present in every membrane cell of the body and on demand eCBs synthesis is regulated by electrical activity and calcium shifts. Novel lipid (lipoxins and resolvins) or peptide (hemopressin) players of the ECS also operate as regulators of physiological allostasis. Indeed, the presence of cannabinoid receptors in intracellular organelles as mitochondria or lysosomes, or in nuclear targets as PPARγ might impact energy consumption, metabolism and cell death. To live a better life implies in a vigilant ECS, through healthy diet selection (based on a balanced omega-3 and -6 polyunsaturated fatty acids), weekly exercises and meditation therapy, all of which regulating eCBs levels, surrounded by a constructive social network. Cannabidiol, a diet supplement has been a major player with anti-inflammatory, anxiolytic, antidepressant, and antioxidant activities. Cognitive challenges and emotional intelligence might strengthen the ECS, which is built on a variety of synapses that modify human behavior. As therapeutically concerned, the ECS is essential for maintaining homeostasis and cannabinoids are promising tools to control innumerous targets.

 

Keywords: THC – tetrahydrocannabinol, cannabidiol, diet, exercise, meditation, anandamide, BDNF, metabolic programming

Introduction

The endocannabinoid system (ECS) controls a widespread and abundant metabolic network. It impacts on many symptoms experienced by adults or children during the COVID-19 pandemics, including chronic pain, lack of exercise, poor diet and gain of weight, mood disorders, as depression, anxiety () or increased stress due to lockdown, social distancing, and job loss, as well as due to exhausting work shifts for intensive care staff (). The ECS has been studied systematically since the elucidation of the structure of tetrahydrocannabinol (THC) from Cannabis (), and later recognized as a physiological circuit breaker with the discovery of membrane receptors, enzymes, and endocannabinoid-like mediators (). Alternatively, more people became interested in meditation and mindfulness healings suggesting that alternative therapies might improve measures of anxiety, depression and pain scores, and possibly on the mechanisms of plastic brain changes on people with a long-term traditional meditation practice (). As the receptors were initially cloned and mapped in the 1990s, it became clear that two major branches emerged from the ECS: one highly enriched in the brain () and its peripheral nerves and the other in the immune system (). Today, a multitude of direct and indirect intra- and extracellular targets in almost all physiological systems constitutes the endocannabinoidome, an ensemble of eCBs and their receptors and metabolic enzymes () to form a multi-facet therapeutic platform (). This is the core of the recent cannabinoid medicine field that claims to improve several maladies as chronic pain and spasticity (), but that still raises many concerns due to controversies of the matter and the adverse effects shown by phytocannabinoids.

What Does the Endocannabinoid System Consist Of?

The ECS is composed of lipid endocannabinoids (eCBs) and peptide (hemopressin derivatives) mediators, their receptors [the most prominent are the type 1 (CB1) and type 2 (CB2) cannabinoid receptors], metabolic enzymes and membrane transporters (Figure 1). CB1 and CB2 are G-protein coupled receptors () highly concentrated on major brain areas () such as neurogenic niches (), that upon activation signal through fast (Ca2+ and K+ currents) () and/or slow pathways, as cyclic AMP-protein kinase A (cAMP-PKA), extracellular signal-regulated (ERK), beta-arrestin, mitogen-activated protein kinase (MAPK) and PI3K (); gene transcription is also turned on by nuclear receptors (of the PPAR family), which increases plasticity (), and are targeted by the ECS.

An external file that holds a picture, illustration, etc. Object name is fnins-15-747229-g001.jpg

The endocannabinoid system (ECS) is composed of lipid endocannabinoids (eCBs), allosteric (lipoxins and resolvins) and peptide (hemopressin derivatives) mediators, their receptors (the cannabinoid type 1 (CB1) and type 2 (CB2), which are activated by phyto- (THC, CBD, and possibly many others) and synthetic cannabinoids (represented by WIN55,212-2, a mixed agonist), metabolic enzymes (FAAH and MAGL, and others) and membrane transporters. Upon activation, CB1 and CB2 signal through fast (Ca2+ and K+ currents) and/or slow pathways, as cyclic AMP-protein kinase A (cAMP-PKA), ıextracellular signal-regulated (ERK), beta-arrestin, mitogen-activated protein kinase (MAPK) and PI3K; in addition, gene transcription is also turned on by nuclear receptors (PPARγ and others).

Lipid eCBs are endogenously generated from membrane phospholipids that contain arachidonic acid (AA) () to derive the N-arachidonoylethanolamide (anandamide or AEA) and 2-arachidonoylglycerol (2-AG). AEA is a partial agonist of both CB1 and CB2 receptors with a higher relative intrinsic efficacy and affinity for CB1 receptors. Alternatively, 2-AG shows a higher potency compared to AEA as a cannabinoid receptor (CB) agonist, binding with the same affinity to both receptors (). Other “weak” eCB [2-arachidonoyl glyceryl ether, O-arachidonoylethanolamide (OEA) and derivatives of long-chain N-acyl-amides, including N-acyl-taurines, N-acyl-serotonins, N-acyl-dopamines, and fatty acid primary amides] might also contribute with different responses, depending on the tissue or the metabolic condition (). Indeed, palmitoyl-ethanolamide (PEA), one of these eCB, when given as a dietetic powder, rescues learning and memory impairments in a triple transgenic mouse model of Alzheimer’s disease (AD) by exerting anti-inflammatory and neuroprotective effects ().

Plant-derived phytocannabinoids, i.e., THC and cannabidiol (CBD), the two most acknowledged metabolites out of hundreds of molecules present in Cannabis sativa L., are highly studied due to their general effects on the brain. Both THC and CBD were isolated in the mid-1960s and display many important effects. THC, for instance, is psychoactive and known to induce relaxation, euphoria, and memory impairment (). However, the misuse of Cannabis might affect the function of the brain and/or induce psychosis at critical developmental stages as pregnancy or adolescence (). Indeed, cannabinoid exposure during prenatal/perinatal and adolescent periods might alter synaptic plasticity in neurodevelopmental processes, in which the ECS plays an essential role (). On the other hand, CBD is a potent anti-inflammatory, anxiolytic, antidepressant, antipsychotic, anticonvulsant, anti-nausea, antioxidant, antiarthritic, and antineoplastic agent (). Although non-psychotomimetic, CBD presents promising therapeutic effects on the brain, known to reduce brain damage associated with neurodegenerative and/or ischemic conditions. It also has positive effects on attenuating psychotic-, anxiety-, and depressive-like behaviors (). Indeed, CBD was able to prevent the development of molecular and behavioral schizophrenia (SCZ)-like alterations in neurodevelopmental animal models, without inducing side effects (). This latter paper shows for the first time that CBD seems both to normalize the D3 receptor expression in gestational methylazoxymethanol acetate (MAM) model of SCZ and to bind preferentially to dopamine D3 receptors, as novel potential mechanism of action. In addition, CBD treatment may normalize perinatal THC-exposed male rats-induced psychopathology by modulating the altered dopaminergic activity and transcriptional regulation of the genes encoding for the cannabinoid CB1 receptor (Cnr1) and the dopamine D2 receptor (Drd2) (). Cannabinoids are not the only compounds that can influence eCB tone; aptly called cannabimimetic, there are several foods, such as dietary and omega (n-3 and n-6) fatty acids as important intermediaries for energy metabolism, influencing feeding behavior, neural plasticity, physical activity (PA), and cognition during aging and activities that can signal through our ECS for optimal health ().

In addition to the lipid agents, a new class of endogenous peptides derived from hemopressin (HP), PVNFKLLSH, a fragment derived of the α-chain of hemoglobin has been recently investigated. HP acts as an inverse agonist of the CB1 receptor, consequently regulating the antinociceptive activity (), food intake (), and inducing oligodendrocyte differentiation () in the subventricular region of the newborn mice (; reviewed in ). HP extended forms (RVD- and VD-HP) are agonists of CB1 receptors (). An HP fragment NFKF was recently shown to promote analgesia, delay seizure induced by pilocarpine, and prevent neurodegeneration in an experimental model of autoimmune encephalomyelitis (). These effects have caught the attention of pharmaceutical companies. In addition, the recent wave of Cannabis legalization in several western countries and the surge of the so-called marijuana stocks have attracted investors and are worth billions of dollars transforming a once abused illicit drug field into a promising area for investors.

Endocannabinoid System Fine-Tune Physiology Regulation

The ECS is an underlying system contributing to homeostasis in many of our body’s physiological and cognitive processes (), including but not limited to mood, memory, appetite, energy, pain, cardiovascular and respiratory function, and neuro-immune modulation. Cannabinoid receptors are highly expressed in the brain and in virtually all peripheral tissues regulating physiological functions directly or indirectly through the autonomic nervous system. Regarding the expression of CB receptors, it is well known that the CB1 receptors are present at very high levels on inhibitory (GABAergic interneurons) and at a lesser extent on excitatory (glutamatergic) terminals (), as well as on neurons expressing dopamine D1 receptors, playing a specific role in the repertoire of different emotional behaviors including social and cognitive activity, which are affected in psychiatric disorders (). Cannabinoid signaling is found in all players of the quadripartite synapse, formed by pre- and postsynaptic neurons, astrocytes, and microglia, in a highly interacting device, adjusting many functions in the Central nervous system (CNS; ). CB1 and CB2 receptors are located both on neurons and glial cells and are considered the main circuit breakers, as activation of pre-synaptic CB1 (and possibly CB2) receptors inhibits the release of the major neurotransmitters glutamate (excitatory) and GABA (inhibitory) (). Also, ATP, the major signal secreted by astrocytes () and microglia () signals through P2Y and P2X purinergic receptors which are modulated by ECs through hemichannels ().

In addition to the canonical pathway mediated by CB1 and/or CB2 receptors, additional targets are also considered as GPR18 and GPR55 (), the transient receptor potential vanilloid 1, TRPV1 () or heterodimers for many different receptors (dopamine, serotonin, and hormones) (), which might increase the complexity of spatial-temporal responses. Indeed, experimental evidence points to the fine-tuning of membrane receptor-interacting proteins, as the cannabinoid receptor-interacting protein 1a (CRIP1a) (), increasing the complexity in terms of cellular localization and functions, ranging from food intake regulation and energy balance to mechanisms of brain plasticity and cancer. Signaling devices are expressed in different cell types, which could act as frameworks to modulate G protein-mediated signaling () and explain several of the conflicting effects exerted by eCBs, phyto-, and synthetic cannabinoids.

N-arachidonoylethanolamide levels are degraded by the fatty acid amide hydrolase (FAAH) enzyme, a serine hydrolase found in cell bodies and dendrites of postsynaptic neurons in major areas of the brain (). eCBs, are known as retrograde messengers [most of the synthetic enzymes are centered post-synaptically, operating on demand, activated by electrical activity, and/or calcium shifts ()]. FAAH inhibitors have attracted interest from the pharmaceutical industry as they prolong the accurately regulated pro-homeostatic actions of AEA (), inducing, for instance, powerful analgesia (). A recent case emerged from a Scottish native that faced a lifelong record of adversities resulting in painful events (hand surgery due to arthritis, joint degeneration, cuts, and burns that healed briefly), with no complaint of discomfort. That lead to the identification of a microdeletion in FAAH conferring reduced expression and activity resulting in high AEA concentrations and pain insensitivity (). As chronic pain is one of the major topics of the XXI century, this might open a new avenue for treatment by targeting drugs or by the use of medical Cannabis ().

Healthy Diet, Supplements, and Natural Products

Balanced diets in macro and micronutrients are fundamental to the correct CNS development and maturation, for allowing structural changes and specific metabolic signals in homeostatic or pathological conditions (). ECS represents a link between dietary lipids and synaptic activity, and it is involved in several mechanisms related to the development and neuroplasticity (). An increasing number of studies have suggested its participation in antioxidant, anti-inflammatory, and cytoprotective mechanisms, indicating the potential therapeutic of this system in some neurological diseases (), as well as in conditions of systemic inflammation and obesity (). Experimental studies of selected diets such as the Mediterranean, which consists of unsaturated lipids from fish, olive oil, fruits, vegetables, whole grains, and legumes/nuts, suggest better physiological parameters decreasing the burden, or avoiding the outcome of cardiovascular disease, stroke, depression, several types of cancer, diabetes, obesity, and dementia (). The Mediterranean diet impacts on the plasma concentrations of eCBs, altering N-acylethanolamines, and their specific ratios in people with lifestyle risk factors for metabolic diseases (), causing changes in the gut microbiome and metabolome (). This is important due to conditions faced by hundreds of millions around the globe exposed to dietary inequalities. In Brazil, for example, a change has been noticed from an undernutrition status in impoverished areas from the Pernambuco State in the 1970–1980s and modeled as the Regional Basic Diet (RBD) to western-type high-fat foods nowadays (). This nutritional transition from chronic consumption of hypoproteic (RBD) or high-fat diets may have consequences to the general health of the population ().

The levels of eCBs and their activity at CBs are influenced by the content of n-6 series derived from linoleic acid (LA, 18:2n-6), and n-3 series derived from alpha-linolenic acid (ALA, 18:3n-3), essential polyunsaturated fatty acids (PUFAs) in the diet (); in addition, activity of biosynthetic and catabolic enzymes of the ECS and the way they exert important roles impact the regulation of appetite and metabolism (). Both AEA and 2-AG are derived from AA of the n-6 family (), while N-docosahexaenoyl-ethanolamine (DHEA), N-eicosapentaenoyl-ethanolamine (EPEA), 2-acylglycerols, 2-docosahexaenoylglycerol (2-DHG), and 2-eicosapentaenoylglycerol (EPG) are derived from the n-3 PUFAs docosahexaenoic acid (DHA) and eicosapentanoic acid (EPA) (Figure 2). Alpha-linolenoylethanolamide (ALEA) is another eCB produced from the n-3 ALA, which is detected in human plasma, and it is responsive to dietary supplementation ().

An external file that holds a picture, illustration, etc. Object name is fnins-15-747229-g002.jpg

Dietary patterns, as the Mediterranean (n-3 series enriched) are linked to better physiological parameters decreasing the outcome of several types of diseases, which consists of unsaturated lipids from fish (and olive oil, fruits, vegetables, whole grains and legumes/nuts), impacting on the levels of eCBs; they are influenced by the content of n-3 series derived from alpha-linolenic acid (ALA, 18:3n-3) and n-6 series (enriched in Western diet) derived from linoleic acid (LA, 18:2n-6), essential polyunsaturated fatty acids (PUFA); both AEA and 2-AG are derived from AA of the n-6 family, while N-docosahexaenoyl-ethanolamine (DHEA) and N-eicosapentaenoyl-ethanolamine (EPEA), are derived from the n-3 PUFAs docosahexaenoic acid (DHA) and eicosapentanoic acid (EPA).

Another class of n-3 PUFA-derived lipid metabolites present in the brain and peripheral organs comes from the crosstalk between eCB and cytochrome P450 (CYP) epoxygenase metabolic pathways. The n-3 eCB epoxides are originated from DHA and EPA to form epoxyeicosatetraenoic acid-ethanolamide (EEQ-EA) and epoxydocosapentaenoic acid-ethanolamide (EDP-EA), respectively. These n-3 endocannabinoid epoxides have anti-inflammatory and vasodilatory properties and can modulate platelet aggregation ().

Considering that diet is the largest source of substrate for the biosynthesis of eCBs in mammals, dietary changes in the n-6/n-3 ratio can directly modulate their levels in tissues and, consequently, their biological functions (). Evidence has shown that deficiency in n-3 during pregnancy and lactation is capable of negatively altering functions mediated by the ECS in the offspring. Young mice, submitted to a maternal n-3 deficient diet, showed an inhibition of long-term depression (LTD) mediated by n-6 eCB and a reduced sensitivity of the CB1 receptor in the prefrontal cortex and nucleus accumbens (); in addition, changes in long-term potentiation (LTP) and LTD in the hippocampus () and in the mitogen activated protein kinases (MAPK) signaling pathway after activation with CB1/CB2 agonists were also detected in the prefrontal cortex and hypothalamus (). These studies suggest that such changes in synaptic plasticity mechanisms may be related to the increase in anxiety- and depression-like behaviors observed in n-3 deprived animals. Thus, n-3 PUFA and the ECS modulate several functions through neurodevelopment including synaptic plasticity mechanisms. Our group has recently shown that changes in maternal dietary DHA levels may impact differently on the ECS and molecular markers highlighted by increased synaptophysin levels in the neonate brain, CB1/2 receptor levels in dams and neonates’ brain, glial fibrillary acidic protein (GFAP) levels, and protein kinase A (PKA) phosphorylation in the cortex and ERK phosphorylation in the hippocampus of the progeny ().

In vitro studies with long chain polyunsaturated fatty acids (LC-PUFAs) DHA or EPA were also able to modulate the ECS. DHA supplementation in hippocampal neuron cultures promoted increased mRNA and protein levels of CB1 and TRPV1 receptors, in a dose-dependent manner (). Indeed, it was reported that addition of DHA and EPA promotes increased levels of 2-AG in neural stem cell cultures. The presence of EPA also increased cell proliferation and activation of the p38-MAPK pathway, showing a relationship between proliferation, eCBs and n-3 derivatives ().

Endocannabinoid system has systemic effects in the regulation of food acquisition, energy sensing and metabolism (). Overactivation of the 2-AG and AEA (derived from AA) stimulate neural mechanisms involved in the appetite and can favor food-related disorders such as obesity and inflammation (). Therefore, a competition for shared biosynthetic pathways between n-3 and n-6 fatty acids and the opposite systemic effects of these lipids might modulate the final action of eCBs in a range of tissues. n-3 derived eCBs from DHA or EPA have anti-inflammatory properties and their chronic supplementation in humans or animals reduces 2-AG and AEA levels (). As a consequence, a lower body mass index () and a preventive effect on the development of obesity have been reported (). The recommended n-6/n-3 ratio for optimal eCB production is 4:1 (). Nevertheless, the current Western diet adopted in many countries with high amounts of vegetable oils enriched with alpha-linoleic fatty acid usually lends itself to ratios closer or higher than 16:1. Thus, dietary supplementation with popular food sources of n-3 such as fish (mackerel, salmon, seabass, and sardines), seaweed, edamame, hemp, chia, and flax seeds, are suggested as a part of a balanced lifestyle. Additionally, the anti-inflammatory, anti-cancer, and hypotriglyceridemic effects of these fatty acids and derived n-3 endocannabinoids are also involved in reproduction control and in the stress response which reinforce actions which are co-preventative and co-therapeutic in the management of several diseases ().

Medicinal plants are part of diet since early stages of human civilization. Thus, evidence-based alternative medicine of the cannabimimetic activity of many natural products, their wide availability and low side effects stimulate future studies for their inclusion as a part of a balanced dietary lifestyle. This could be especially relevant for targeting endocannabinoid dysregulation. Complementary to dietary interventions using balanced levels of essential fatty acids, natural bioactive compounds obtained in several plants can act as phytocannabinoids, showing affinity, adequate potency, and efficacy on CB receptors, and some of them might also act on metabolizing enzymes, thus modulating the ECS activity (). Compared to synthetically derived cannabinoids, naturally derived molecules induce few adverse effects and their use as promising and emerging therapeutic alternative has been investigated for treatment of several metabolic or neurodegenerative diseases ().

The diverse chemical classes of these phytocannabinoids ligands (Figure 3) include alkaloids, terpenes, terpenoids, and polyphenols (). The sesquiterpene β-caryophyllene, for example, can be found in essential oil of cloves, oregano, cinnamon, black pepper, hemp, rosemary, and hops (). It is commonly used in food, cosmetics, and fragrances as flavoring agent and exerts potent cannabimimetic anti-inflammatory actions including CB2-dependent therapeutic effects in cerebral ischemia (), insulin resistance (), glutamate neurotoxicity (), renal injury (), anxiety and depression (), neuropathic pain (), and AD ().

An external file that holds a picture, illustration, etc. Object name is fnins-15-747229-g003.jpg

Cannabimimetic activity of bioactive substances obtained in foods and medicinal plants that if included in the diet could indirectly exert immunomodulatory and beneficial effects to the health. (1) turmeric root; (2) grapes; (3) green tea; (4) Maytenus senegalensis (Lam.) fruit and roots; (5) black peppers; and (6) blueberries. Arrows indicate activation of CB1 and/or CB2 receptors. Dashed arrows indicate inhibition of endocannabinoid transporters (EMT) or enzymatic metabolism via FAAH (Fatty acid amide hydrolase) or MAGL (Monoacylglycerol lipase). DAGL: Diacylglycerol lipase; NAPE-PLD: N-acyl phosphatidylethanolamine phospholipase D; NAT: N-acetyltransferase; 2-AG: 2-Arachidonoylglycerol.

Polyphenol compounds found in the leaves of teas, in several fruits and legumes, such as catechins, exhibit binding properties with CB1 and CB2 receptors in a dose-dependent manner (). In addition, curcumin, another polyphenol that inhibits tumor growth by increasing ROS levels and the antioxidant glutathione (GSH) () has been linked to a cannabinoid activity in multiple physiological systems, such as alternative treatments for inflammatory bowel disease, other digestive diseases or liver fibrosis (), alone or in the presence of hemopressin ().

Resveratrol is a compound present in fruits and plants with beneficial effects for the health, whose pharmacological properties have been widely investigated. Resveratrol exhibits peripheral antinociception through opioid (μOR) and cannabinoid (CB1) receptor activation in hyperalgesia induced by carrageenan in the paw withdrawal method (). The extract of several medicinal plants have been analyzed regarding their ability to bind on CBs (). Cannabinoid-dependent beneficial effects of these extracts have been indicated on neuropathic pain, immunomodulation, inflammation, lung injury, obesity, colon cancer, osteoporosis, and diabetes ().

Exercise

Routine PA has the potential to improve several physiological parameters at different organs, leading to modifications in metabolic, cardiovascular, and immune routes. It is common sense that PA provides a sharp memory, better cognition, and helps with sleep cycle regulation. Indeed, PA has been shown to revert some of the deleterious effects of a sedentary lifestyle, delay brain aging, and neurodegenerative pathologies such as AD, diabetes, and multiple sclerosis (). Aerobic fitness (essential for endurance activity) and aerobic capacity (measured as maximal oxygen consumption during exercise, VO2 max) results in major adaptations of the cardiorespiratory and neuromuscular systems that increase the distribution of oxygen to the mitochondria and enable a tighter regulation of muscle metabolism (), normalizing blood pressure with less risk of stroke, preventing, and treating cardiometabolic diseases like obesity and type 2 diabetes and cardiovascular diseases. Also, it prevents other chronic disorders (cancer, hypertension, obesity, depression, and osteoporosis) and premature death (). It is a common belief that most of the reward induced by acute or chronic exercises (reward, nociception, mood behavior, anxiety, and performance) are in part related to the release of endorphins and interactions with multiple opioid (mu, kappa, and delta) receptors and/or sensitivity shifts on the receptors ().

However, in the last two decades, irrefutable evidence demonstrated that the ECS is also a major player in systemic energy metabolism, inflammation, appetite control, and pleasure (acute anxiolysis, analgesia, antidepressant effects, sedation, and euphoria) of the so-called runner’s high (). In terms of mechanisms, voluntary exercise controls hippocampal plasticity independently to the ECS. Voluntary exercise increased the proliferation of progenitor cells, as evidenced by the increase in the number of Ki-67 positive cells in the granule cell layer of the dentate gyrus (DG) in the hippocampus. However, this effect was abrogated by concurrent treatment with AM251, a CB1 antagonist, indicating that the increase in endocannabinoid signaling in the hippocampus is required for the exercise-induced increase in cell proliferation. These data demonstrate that the ECS in the hippocampus is sensitive to environmental changes and suggest that it is a mediator of exercise-induced plasticity (). Rats submitted to forced exercise (treadmill-running training) show an improved expression of LTP in the DG and enhanced object recognition learning (). Functional changes are linked with an increase in the expression of brain-derived neurotrophic factor (BDNF), a key player for exercise-induced brain plasticity (). As higher BDNF levels and ECS activation could have positive effects on depression, an investigation was made on intense exercise in 11 healthy trained male cyclists. The plasma levels of AEA and BDNF were increased, whereas 2-AG concentrations remained stable during exercise and the 15 min recovery (). This indicates that an increase in AEA during exercise might be one of the factors involved in the exercise-induced increase in peripheral BDNF levels and that AEA high levels during recovery might delay the return of BDNF to basal levels (Figure 4). Indeed, recent data described that aerobic exercise induced increases in peripheral AEA and BDNF which play a role in enhancing consolidation of fear extinction learning (). Therefore, an increase in the peripheral levels of AEA and BDNF might be a mechanism underlying neuroplasticity and antidepressant effects of exercise () and might be a promising candidate to reduced threat expectancies following reinstatement among women with posttraumatic stress disorder ().

An external file that holds a picture, illustration, etc. Object name is fnins-15-747229-g004.jpg

Exercise reverts some of the collateral effects of a sedentary lifestyle, and has the potential to improve metabolic, cardiovascular, and immune parameters, providing a better memory, cognition, and sleep cycle regulation, delaying brain aging and chronic and neurodegenerative pathologies. It is a common belief that most of the reward induced by acute or chronic exercises (reward, nociception, mood behavior, anxiety, and performance) are related to the release of endorphins and eCBs, which interact with multiple opioid (mu, kappa, and delta) and cannabinoid receptors; Irrefutable evidence demonstrate that the ECS is a major player in systemic energy metabolism, inflammation, appetite control, and pleasure (acute anxiolysis, analgesia, antidepressant effects, sedation, and euphoria) of the so-called runner’s high.

Curiously, eCBs are elevated not only with acute exercise but also with obesity. Transcriptomic response of skeletal muscle to acute and chronic aerobic and resistance exercise confirms the expression of major cannabinoid players in the synthesis and breakdown of eCBs, possibly involved with the anti-inflammatory effect of exercise (). Recent multi-omic studies (metabolome, lipidome, immunome, proteome, and transcriptome) performed on plasma and peripheral blood mononuclear cells from volunteers subjected to acute PA (before and after a controlled session of symptom-limited exercise) revealed thousands of changes on analytes and a coordinated strategy of procedures involving energy metabolism, oxidative stress, inflammation, tissue repair, and growth factor response, as well as regulatory pathways (). An increase in eCBs levels is correlated with metabolic disorders as higher lipogenesis is found in the liver and adipocytes, and lower insulin sensitivity in peripheral tissues (). Finally, Cannabis use has increased in the recent past, in large part due to decriminalization. Even though the ECS is central to the benefits induced by PA, it is currently unknown if Cannabis users present different athletic performance and recovery (). Based on the literature, Cannabis does not appear to be an enhancer to affect performance, neither is known regarding the use among elite athletes (). Recently, the discussion has been centered on CBD, a phytocannabinoid that was removed from the list of prohibited substances – in or out of competition – from the World Anti-Doping Agency (WADA) and the United States Anti-Doping Agency (USADA). Although CBD is not prohibited, athletes should be alerted some CBD oils and tinctures extracted from Cannabis plants may also contain THC and other cannabinoids that could result in a positive test for a prohibited cannabinoid.1

Meditation

Meditation is a multifaceted process that allies strength, endurance, flexibility and enables self-control to create an awareness of concentration, calmness, and well-being, presenting both physical and mental health benefits (). It impacts cognition, memory, social, and emotional control, which enhances the autonomic control of the nervous system and peripheral targets as cardiovascular, neuroimmune, and renal physiology (). Mind-body exercises control several brain structures, altering neural activity and functional connectivity, predominantly in the prefrontal cortex, hippocampus/medial temporal lobe, lateral temporal lobe, insula, and the cingulate cortex (). Although the molecular mechanisms involved are not fully understood, it is clear that several transmitter systems and brain areas are involved () and the ECS has gained attention in the pursue of happiness or treat diseases (). Regular mindfulness practice has consequences on physiological and psychological functioning with performance outcomes in sports () and regular yoga has improved sleep quality and work stress (). Data on regular yoga users (transcendental meditation) faced modest average reductions in blood pressure (). Depression or anxiety have also been alternatively treated with non-conventional interventions, including exercise, yoga and meditation (). In patients with mild-to-moderate Parkinson’s disease (PD), mindfulness yoga has been shown to be effective in improving motor dysfunction and mobility (). Curiously, a novel concept labeled as Spiritual Fitness which pursues stress reduction, basic and psycho/spiritual wellbeing is being used in AD prevention (). Adults under cancer treatment have also gained benefits under yoga practice for improving psychological outcomes, possibly also improving physical symptoms (); however, more rigorous and large groups designed randomized trials are needed () to address the psychosocial needs of cancer patients.

From a millennial background in the Indian culture with a focus on the four foundations of mindfulness – body, feelings, mind, and dhammas – the sense of truth, healing named as yoga, meditation has become widely praised in the Western societies, including used as medical and psychological therapies for stress-related physical and mental disorders (). Although the biological mechanisms in terms of the effect on the brain and body are poorly understood, the molecular correlates of these effects operate through the major neurochemical system, amines (acetylcholine, dopamine, and serotonin) and the putative release of endogenous cannabinoids and endorphins, which may exert salutary effects on mood/anhedonia (). In a double-blind, randomized, placebo-controlled study with 15 healthy experienced mindfulness meditation practitioners, participants rated the pain of a cold stimulus before and after a mindfulness meditation session. Participants were randomized to receive either intravenous naloxone or saline, after which they meditated again, and rated the same stimulus. The conclusion was that meditation involves endogenous opioid pathways mediating its analgesic effect, which could hold promising therapeutic implications and elucidation for the mechanisms involved in human pain modulation ().

It is suggested that volitional changes in breathing patterns can activate primary control centers for descending pain/cold stimuli in periaqueductal gray, initiating a stress-induced analgesic response mediated by eCB/endorphin release. The analgesic effects and the feelings of euphoria generated by eCB release are prolonged via a top-down “outcome expectancy” control mechanism regulated by cortical areas (). An experimental study conducted on adults before and after the 4-day Isha Yoga Bhava Spandana Program evaluated AEA, 2-AG, 1-arachidonoylglycerol (1-AG), DEA, oleoylethanolamide (OLA), and BDNF on anxiety and depression through psychological scales. Authors reported changes in major eCBs levels (Figure 5), with increase in AEA, 2-AG, 1-AG, DEA, and BDNF after meditation, suggesting a participation for these biomarkers in the underlying mechanism of meditation (). Indeed, increased BDNF levels has been linked in meditative practices and brain health in a 3-month yoga and meditation retreat assessed with psychometric measures, circadian salivary cortisol levels, and pro- and anti-inflammatory cytokines (). In addition, a 3-month meditation retreat has been evaluated on telomerase activity and the experience of stress, with participants controlled in concentrative meditation techniques and collection of peripheral blood mononuclear cell samples for telomerase activity. Authors reported a clear link between meditation and positive psychological change with telomerase activity ().

An external file that holds a picture, illustration, etc. Object name is fnins-15-747229-g005.jpg

Regular mindfulness practice has consequences on physiological and psychological functioning with performance outcomes in sports, improving sleep quality and work stress. Data on regular yoga users (transcendental meditation) faced modest average reductions in blood pressure. Depression or anxiety have also been alternatively treated with non-conventional interventions, including exercise, yoga, and meditation. In addition, patients with mild-to-moderate Parkinson’s disease, mindfulness yoga has been shown to be effective in improving motor dysfunction and mobility. An experimental study conducted on adults before and after the 4-day Isha Yoga Bhava Spandana Program evaluated AEA, 2-AG, 1-arachidonoylglycerol (1-AG), DEA, oleoylethanolamide (OLA), and BDNF on anxiety and depression through psychological scales. Authors reported changes in major eCBs levels, with increase in AEA, 2-AG, 1-AG, DEA, and BDNF after meditation, suggesting a participation for these biomarkers in the underlying mechanism of meditation (). Indeed, increased BDNF levels has been linked in meditative practices and brain health in a 3-month yoga and meditation retreat assessed with psychometric measures, circadian salivary cortisol levels, and pro- and anti-inflammatory cytokines (). In addition, a 3-month meditation retreat has been evaluated on telomerase activity and the experience of stress, with participants controlled in concentrative meditation techniques and collection of peripheral blood mononuclear cell samples for telomerase activity. Authors reported a clear link between meditation and positive psychological change with telomerase activity ().

The suggested participation of the ECS on health benefits of meditation may have direct and undirect roles of the cannabinoid signaling. The undirect effects may arise from the ECS regulation upon the “stress axis” hypothalamus-pituitary-adrenal (HPA) that controls glucocorticoid (cortisol or corticosterone) release (). Corticotropin-releasing hormone (CRH) neurons of the paraventricular hypothalamic nucleus (PVN) receive and integrate inputs coming from brain areas comprising the limbic system that are responsible for processing psychological stressors, such as pre-frontal cortex, medial amygdala, paraventricular thalamic nucleus, among others (). The ECS is widely expressed in all components of the limbic system and HPA axis (). The afferences from the limbic system establish synaptic contact with local interneurons of the PVN that inhibit or stimulate the CRHergic neurons through GABAergic or glutamatergic synapses (). Recent studies demonstrated that the eCBs act like a gatekeeper of the HPA axis, decreasing the activity of the CRHergic neurons tonically, acting like a stress-buffer system ().

Experimental evidence supports the buffering role of the ECS on stress response. Treatment with CB1 antagonist (SR141716A) results in increased corticosterone release in mice () and, in agreement, CB1 knockout mice have increased basal secretion of adrenocorticotropin hormone and corticosterone (). Additionally, a mice model of CB deficiency (Cnr–/–) is highly sensitive to chronic social defeat stress protocol with altered glucocorticoid levels, suggesting dysregulation of the HPA axis ().

Endocannabinoid System Meets Mitochondria: Relevance for the Brain

In order to maintain its cellular processes (including neurotransmission, protein and lipid synthesis, and others), CNS presents a high metabolic activity. Therefore, continuous energy and oxygen supply is required (). Mitochondria are then pivotal for normal brain function. Despite the notorious role of mitochondria for cellular energetics and redox homeostasis, these organelles are also involved in a myriad of other physiological and pathophysiological mechanisms in the cells (). Mitochondria respond in a dynamic fashion to cope with cellular demands ().

Although the mainstream signaling of CBs initiates at the plasma membrane and invades the cytoplasm and intracellular organelles, CB1 expression is predominantly intracellular (). Functional CB1 receptors are found on intracellular compartments as endosomes () and mitochondria (). The biological relevance of this unorthodox localization of CB1 receptors, particularly in mitochondria, is still a matter of debate.

The seminal work from  showed that either endocannabinoids or exogenous cannabinoids can activate mitochondrial CB1 receptors in the brain. Such activation tones down respiration, as well as PKA activity and the intramitochondrial levels of the second messenger cyclic AMP (cAMP). Genetic manipulation tools allowed the observation that the activation of mitochondrial CB1 receptors in the hippocampus leads to memory impairment (). Activation of the astrocytic mitochondrial CB1 receptors decreases glucose metabolism and lactate formation in the brain, impacting neuronal functioning, and animal behavior (). It should be considered that higher brain functions present demanding energy budget and mitochondria are pivotal to the maintenance of brain bioenergetics and the metabolism of neurotransmitters (). The ECS system seem to be differentially affected depending on the stage of brain development (), which represents a period of challenging metabolic demands (). Therefore, these observations indicate that alterations on mitochondrial CB1 receptors in the brain could represent a novel therapeutical tool, as well as a possible mechanism underlying the behavioral alterations elicited by cannabinoid consumption.

It has been reported that the levels of the eCB 2-oleoylglycerol are low in the brain of mice lacking carnitine palmitoyltransferase-1c (CPT1c) (). CPT1c modulates energy homeostasis () and shows high homology with the isozymes CPT1a and CPT1b but is restricted to neurons (). Whilst CPT1a and CPT1b are found in mitochondria, where they bind acyl moieties to carnitine (), CPT1c is expressed in endoplasmic reticulum and its biological function is still uncertain (). Whether on the one hand it is still to be defined if the effect of CPT1c on the metabolism of endogenous cannabinoids is either direct or indirect, on the other hand recent reports implicate CPT1c with mitochondrial function (). Mitochondrial adaptations also seem to be involved in the modulation of feeding behavior elicited by ligands of CB1 receptors (); for a deeper discussion on cannabinoids affecting feeding behavior refer to the section “Endocannabinoid System and the Neuroendocrine Regulation of Energy Metabolism.”

Cannabis and the Endocannabinoid System

Cannabis use dates to the ancient Eurasian societies, with evidence pointing to the territories of modern China and Romania as the oldest sites of Cannabis use (plant and seeds) for general purposes (). A recent study found burned traces of the plant in wooden braziers from a cemetery in western China. The artifacts dated back 2500 years (500 BCE). Further phytochemical analyses revealed an abundance of psychoactive compounds in the samples, thus suggesting that Cannabis was smoked as a way of provoking ritualistic or religious experiences (). Since then, Cannabis consumption has undergone a series of social transformations, going from a frequently prescribed medicine up until the first decades of the 20th century to a highly illegal drug. Cannabis is regaining space in health care (), quite possibly, starting a wave of legal precedents toward recreational use worldwide (). How does Cannabis modulate the ECS? Which are the main consequences of marijuana consumption on the classically recognized ECS properties?

An important concept to have in mind while discussing Cannabis is that plants have been the main source of medicine prior to the industrial revolution. In such context, the overall effects of C. sativa in the human body were well-known long before it elicited any interest from the scientific community. In general, Cannabis consumption extenuates the physiological effects attributed to the ECS, that is, “relax, eat, sleep, forget and protect” (). After a single administration of THC, it rapidly migrates from the blood to the brain and other high perfusion tissues. Then, it takes up to 2 days for the substance to reach the highest concentrations in low perfusion tissues, and up to 10 days until it is fully stored in the adipose tissue (). Coinciding with the presence of THC in the brain, the psychotropic effects of Cannabis also start within minutes after use and can last for a few hours.

The first and most reported effects of Cannabis start right after consumption, and they are highly associated with the relaxation component of the ECS. Effects on mood are generally described as feelings of decreased anxiety, alertness, depression, and tension. Also, it seems to promote sociability if the user is exposed to a favorable environment. At higher doses, Cannabis users may experience somewhat opposed effects such as increased anxiety, paranoia, psychosis, and panic. Perception of color, time, and space are also distorted, and may include hallucinations with high doses. Decreased cognitive and motor skills were repeatedly shown to affect even the experienced user, increasing by a significant proportion the risk of motor vehicle accidents. The consumption of alcohol and other CNS depressants are additive to the cognitive and motor effects of Cannabis, as reviewed by .

The ability of Cannabis to positively regulate food intake in humans raised considerable controversy in the 1970s, mainly because most animal-derived data pointed toward decreased instead of increased consumption after exposure to marijuana (). Later, investigations revealed that, in fact, after crossing a certain threshold of Cannabis, humans tend to increase their daily food intake by up to 1,000 calories. Interestingly, in all scenarios examined the high caloric consumption was achieved through eating more snacks instead of bigger meals (). Indeed, chronic Cannabis use can increase adiposity and insulin resistance, possibly through its sustained orexigenic properties (). More recent studies with knockout animals and receptor antagonists were able to include the cannabinoid and endocannabinoid agents in the orexigenic substance category (). Hypothalamic centers are stimulated by phytocannabinoids to induce food-seeking behavior and to modulate hormone release (). In the nucleus accumbens it increases motivation for palatable food. Finally, cannabinoids control several endocrine mechanisms in the liver, adipose tissue, muscles, and the gastrointestinal tract, as reviewed by .

Regarding the sleep-inducing effects of Cannabis, studies have yielded mixed results. This apparent heterogeneity may stem from the variable THC/CBD proportions and concentrations found in Cannabis samples across studies. Overall, research indicate that marijuana consumption has short-term benefits for the treatment of sleep conditions, and that it progressively builds tolerance on the user up to a point where chronicity causes complete habituation. Some suggest that a higher proportion of CBD may reduce tolerance and extend the sleep benefits of cannabinoid-based treatments (). In fact, phase I–III studies with a 1:1 THC:CDB compound showed improved sleep quality for patients with relevant pain conditions (). On a different perspective, sleep deprivation is shown to correlate with increased likelihood of marijuana use among teenagers, revealing that the benefits associated with marijuana have reached public knowledge and may influence behavior and substance use (). Another highly reported effect of marijuana is its ability to impair short- and long-term memory.  found that teenagers exposed to marijuana develop short-term memory deficits lasting for up to 6 weeks, which provided support to the previous evidence and helped consolidate the clinical landscape for adolescent Cannabis consumption (). A newly published meta-analysis confirmed a relevant association between marijuana and both short- and long-term memory loss. The study, however, highlights that the effect sizes emerging from these correlations were considerably small, suggesting a contrast with neuroimaging studies associating Cannabis-induced memory loss and the structural changes found in areas such as the hippocampus (). In addition to memory impairment, it is reasonable to associate Cannabis with problems in attention and the ability to process complex information. This effect may persist for weeks, months, or years, depending on the chronicity and frequency of use (). In a functional magnetic resonance study from 2006, working memory and selective attention of frequent but moderate Cannabis users were compared to that of healthy non-users. Except for an alteration in brain activity on the left parietal superior cortex, researchers found no support for the hypothesis of memory and attention deficits emerging from moderate Cannabis use (). A later review of the evidence regarding the chronic effects of marijuana abuse has shown that, although most effects emerging from the plant are acute and tend to fade away with time, there seems to exist some risk of decision-making impairment for the long-term heavy user ().

Some Voxel-based morphometry studies, on the other hand, have shown that chronic users may be subject to reduction of gray matter (GM) in several areas of the brain. For instance, a decreased GM was reported on the medial temporal cortex (cognitive and emotional functions), temporal pole (emotional and social behavior), parahippocampal gyrus (spatial memory), insula (roles in addiction and psychiatric disorders), and the orbitofrontal cortex (emotion and memory) of regular Cannabis users (). Demirakca and coworkers investigated GM from the hippocampus of recreational marijuana users. Accordingly, the group found reduced GM volume on the right anterior hippocampus, with further correlation analyses showing a potential protective role for CBD among study participants ().

Corroborating with (), a study from  showed that chronic exposure to marijuana reduces the volume of GM in the orbitofrontal cortex. Further, the brain of frequent Cannabis users revealed complex structural changes emerging as a function of onset and duration of use (). Despite these reported alterations, the debate remains on whether they are fully or partially reversible under complete abstinence. This is especially important for patients presenting with PTSD and chronic pain, conditions in which treatment with Cannabis is effective, but may promote tolerance after prolonged use ().

Finally, an important discussion is necessary when long-term effects on cognition of medical cannabis (MC) use is compared to recreational cannabis, especially in those with adolescent onset. Comparison of MC patients from recreational consumers considers diverse factors as motives for use, product selection, and age of onset, and a recent study evaluated cognitive and clinical measures in well-characterized MC patients over 1 year (). MC patients finalized a baseline visit prior to initiating MC and evaluations following 3, 6, and 12 months of treatment, performing a neurocognitive battery assessing executive function, verbal learning/memory, and clinical scales assessing mood, anxiety, and sleep. Exposure to THC and CBD was also measured. Authors reported that MC patients exhibited significant enhancements on measures of executive function and clinical state over the course of 12 months; clinical improvement was associated with higher CBD use. Therefore, MC patients may show improvements rather than impaired executive function over time (). As Cannabis research remains in its infancy (), further studies are necessary to evaluate differences between recreational and MC use to identify potential mechanisms related to cognitive changes and the role of clinical improvement.

Although the molecular mechanisms underlying Cannabis-induced cognitive deficits are still elusive, three mechanisms have been proposed as necessary for these effects to emerge. First, hippocampal activation of CB1 receptors seems to be more pronounced on GABAergic than on glutamatergic populations of neurons, thus inducing excess activation of glutamate receptors in the hippocampus, which leads to molecular signals that impair cognitive processing. Second, cannabinoids interfere with choline, adenosine (A2 receptors) and serotonin signaling, thus affecting the fine tuning of memory consolidation. Third, the decrease in cell metabolism by activation of mitochondrial CB1 receptors may extenuate the first and second mechanisms ().

Fighting Neurodegenerative Diseases With a Strong Endocannabinoid System

There is a growing interest to reveal novel active compounds in the pharmaceutical field to improve health and longevity of the elderly population. The average life expectancy of the global population increased to 80 years in the developed countries, compared to 50 years in the early 20th century (). People can expect to live into their 60s and beyond, as a result in large reductions in mortality at younger ages. As high-income countries continue to increase in life expectancy among those who are older, a child born in Brazil can expect to live 20 years longer than one born just 50 years ago (). However, rising life expectancy in developed countries has as consequence the emergency of primary risk factors for neurodegenerative diseases associated with aging. Aging is the primary risk factor for most neurodegenerative diseases, and one in 10 individuals aged more than 65 years manifest symptoms of AD and its prevalence continues to advance with increasing age. PD and AD are among the most common neurodegenerative disorders, affecting millions of people worldwide (). Both diseases have no cure, thus the current treatments only reduce the main symptoms. In this sense, searching new targets to prevent and/or impair the progression of these diseases is highly desirable.

Components of the ECS are expressed in the basal ganglia neural circuits, which modulate dopaminergic, GABAergic and glutamatergic signaling. This network is specially impaired during PD due to death of dopaminergic neurons of the substantia nigra pars compacta (SNpc) (). Disturbances in the ECS homeostasis have already been observed in cerebral areas associated with PD pathology in humans, as well as in animal models. CB1 receptor mRNA is reduced in basal ganglia of post-mortem brain of individuals with PD (); in addition, levels of AEA are increased in the cerebrospinal fluid in untreated PD patients endogenous (). Similarly, in the 6-hydroxydopamine (6-OHDA)-induced lesion model in rats the expression of the CB1 receptor was significantly reduced in the substantia nigra pars reticulata (SNpr) (), while CB2 receptor increased in the striatum, followed by an enhance in microglial and astrocyte activation (). Additionally, using the same animal model, AEA levels are increased while FAAH activity is reduced in the striatum, supporting a boost of the ECS, and probably reflecting a compensatory mechanism to counteract chronic dopamine depletion (). Similarly, as Huntington’s disease progress, CBs are also severely reduced in all regions of the basal ganglia implying a potential role for cannabinoids in the progression of neurodegeneration in Huntington’s disease ().

Modulatory effects of the ECS in nigrostriatal pathway support studies targeting this system as a therapeutic strategy in PD. In animal models of PD, CB1 or CB2 synthetic agonists as well as inhibitors of FAAH or MAGL improved motor impairments and induced neuroprotection (). Likewise, treatment with CBD also enhances neuroprotection, both in vitro and in vivo ().

In open-label observational studies, smoking Cannabis improved motor symptoms, such as tremor, rigidity, and bradykinesia in Parkinson’s patients, and ameliorated sleep and pain scores (). Moreover, purified CBD has shown to produce positive effects specially to treat non-motor symptoms of PD, improving quality of life and mental health in patients ().

The roles of the ECS regulating immune and cognitive functions also support its modulation as a potential novel therapeutic target in AD. Nevertheless, findings regarding CB1 receptor expression in this disease are still unclear and the outcomes variable. In the 3×Tg-AD transgenic mice model, CB1 mRNA is increased in the prefrontal cortex, dorsal hippocampus, and basolateral amygdala complex, while decreased in ventral hippocampus of animals with 6 and 12 months of age, but not at 2 months of age (). Interestingly, it was observed in human AD brain samples an hyperactivation of CB1 receptor in earlier stages and a progressive decrease in advanced stages of the disease (). These results suggest that alterations in the ECS might be age and/or pathology-dependent, indicating a relevant issue to be considered in therapeutic approaches. In contrast, other studies showed that CB1R immunocontent was unchanged in different cortical regions and hippocampus of human post-mortem samples, and in cortical areas evaluated by positron emission tomography in individuals with AD pathology ().

On the other hand, CB2R, MAGL, and FAAH are increased adjacent to senile amyloid plaques associated with microglia and/or astrocytes, exhibiting positive correlation with Alzheimer’s progression and probably regulating inflammatory mechanisms (). In fact, activation of CB2 receptor protects hippocampal neurons from Aβ1-42 toxicity (). Otherwise, transgenic amyloid mice lacking CB2 receptor expression present an increase in plaque deposition and plaque-associated microglia, in addition to high soluble Aβ42 levels in the brain (). Additionally, cannabinoid agonists (HU-210, WIN55,212-2, and JWH-133) and JZL184, a MAGL inhibitor, have anti-inflammatory and neuroprotective effects, decreasing microglia effects and reducing the total Aβ burden in vitro () and its precursors in the APdE9 mouse model (). ACEA (arachidonyl-2-chloroethylamide), a selective cannabinoid CB1 receptor agonist, also increases cortical neurons viability exposed to Aβ-42 oligomers, inducing cognitive improvement in AβPP/PS1 mice. These effects are correlated with a decreased astroglial reactivity and production of pro-inflammatory proteins, since ACEA did not impair Aβ aggregation ().

Similarly, CBD and THC have demonstrated neuroprotection in chronically treated AβPP/PS1 mice showing improvements in memory tasks and a decrease in soluble Aβ42 levels, astrogliosis, and several neuroinflammation markers (). Also, CBD alone prevented the development of a social recognition deficit in the same animal model (). Furthermore, in vitro assays showed that CBD shows neuroprotective effects in PC12 cells through Wnt/β-catenin pathway in Aβ-induced toxicity model ().

Although the current findings still do not validate a direct effect of the cannabinoid-based medicine in memory or cognition in AD patients, other symptoms might be alleviated using this approach. Data from mice suggest that treatment with CB1 receptor antagonists might restore memory capacity in animals administered with beta-amyloid fragments that lead to memory disturbances (). Alternatively, VDM-11, an inhibitor of eCB cellular reuptake, increased rat hippocampal and mouse brain eCB levels, reversing hippocampal damage in rats, and loss of memory retention in the passive avoidance test in mice, when administered from the 3rd day after beta-amyloid peptide (1–42) injection (). Therefore, early, as opposed to late, pharmacological enhancement of brain eCB levels might protect against beta-amyloid neurotoxicity and its consequences, reviewed in . In severely demented patients, a prospective observational study showed that the use of oral Cannabis extract, with THC/CBD, significantly improved behavior problems, reducing rigidity, and simplifying daily care (). Moreover, medical Cannabis oil enriched in THC has differential effects on the Neuropsychiatric Inventory (NPI) scale, probably dependent on the duration and dosage ().

Taken together, a growing number of studies have demonstrated beneficial effects of the ECS activation which has proven an excellent target for the treatment of neurodegenerative disease, reducing significative symptoms and improving well-being in these individuals.

Endocannabinoid System and the Neuroendocrine Regulation of Energy Metabolism

Endocannabinoid System and the Hypothalamus – Adipose Tissue Axis in Obesity

Obesity is a major health issue () and no country succeeded in decreasing the number of obese individuals in the last decades, indicating the limitation of the worldwide public health policies (). The obesity etiology is multifactorial with interactions of the genetic background and environmental cues (malnutrition, poor PA, toxicant exposure, and stress) that result in unfavorable metabolic phenotype (). Obesity results from an imbalance between energy intake and expenditure, with the hypothalamus as a major regulator in the CNS.

The hypothalamus is an evolutionarily ancient part of the brain and acts as an integrating node since peripheral inputs are brought together in this region (). The hypothalamus is a master homeostatic regulator, capable of modulating activities that are crucial to life, such as energy homeostasis () and glycemic control (). Interestingly, in obesity and the high-fat diet intake, afferent signals can be differently received and sensed by subsets of hypothalamic nuclei, contributing to the development of metabolic disorders ().

The hypothalamus receives information on the status of body energy storages through sensory innervation and hormone secretion mainly from the white adipose tissue (WAT) and gastrointestinal tract (). In this context, the adipocyte-derived hormone leptin is a key factor because it is produced according to nutritional status and adipose tissue mass (). Leptin activates subsets of hypothalamic neuronal populations, inducing an anorexigenic effect, increasing energy expenditure, and acting as an antidiabetic signal (). Obese subjects frequently present hyperleptinemia but leptin resistance (), which contributes to the positive energy balance due to several mechanisms, including the over activation of the ECS signaling in the CNS () and adipose tissue ().

Hypothalamic leptin action leads to phosphorylation of STAT3 (signal transducer and activator of transcription 3) (pSTAT3) and is especially critical for hypothalamus maturation (). Interestingly, leptin-deficient obese mice or diet-induced obese mice present increased levels of CB1 and DAGL in the lateral hypothalamus (), evidencing an inverse relationship between leptin and ECS signaling.

In a rat model of maternal obesity, maternal high-fat diet intake during pregnancy down-regulates hypothalamic STAT3 in neonate rat offspring associated with hypoleptinemia only in male pups. This profile occurred in parallel to increased levels of CBs in the hypothalamus of the neonate offspring (). Surprisingly, ECS changes were observed before obesity and hyperinsulinemia development in the offspring () and remains until adulthood (). The maternal high-fat diet also increases plasma –n-6/n-3 ratio in newborn rat offspring (), which might indicate an increased risk factor for metabolic disorders and over activation of the ECS signaling (). This profile also suggests a disruption in the brain-adipose tissue axis for appetite regulation, since the adipose tissue lipid profile impacts the local eCB content, while the FAAH inhibition leads to diet-induced hyperphagia in adult genetically modified mice ().

The overall balance between the anorexigenic and orexigenic hypothalamic neuropeptides defines the final metabolic outcome, and CB1 activation modulates feeding by enhancing the orexigenic signals and preference for fat (). In a mice model, the CB1 activation specifically in hypothalamic proopiomelanocortin (POMC) neurons increases food intake by increasing selectively the production of β-endorphin, an orexigenic peptide involved in reward, from POMC cleavage (). In leptin-deficient obese mice, CB1-expressing presynaptic neurons change from glutamatergic to predominantly GABAergic in the lateral hypothalamic area, and because CB1 is associated with Gi/o protein, this remodeling results in increased orexin-A, an orexigenic peptide (). In rats, the CB1 activation decreases hypothalamic serotonergic activity, an important satiety signal, and induces disinhibition of GABA release to stimulate food intake ().

Cannabinoid receptor type 1 activation promotes the conservation of energy not only promoting food intake by hypothalamic mechanisms but also inhibiting energy expenditure by reducing the uncoupling protein 1 (UCP1) expression and thermogenesis in the brown adipose tissue (BAT), which favors the WAT expansion (). CB1 density in the brain, BAT, and WAT of overweight subjects are modified compared to lean subjected, reflecting the impairment of ECS in obesity (). CB1 signaling also activates lipogenesis and adipogenesis in WAT depots (), such as visceral (VIS) and subcutaneous (SUB), which present structural and functional differences associated with a CB1 depot-specific expression. The VIS WAT expansion is a greater predictor of mortality than SUB WAT excess (). CB1 expression is lower in VIS WAT than in SUB WAT of lean subjects, while there is no differential CB1 expression between WAT depots in obese subjects (). CB1 gene expression is twofold higher in SUB WAT from type 2 diabetes subjects, as compared to control subjects ().

Regarding the role of CB2 in energy metabolism, its role as a pro- or anti-inflammatory in the central and peripheral tissues is controversial (). Studies have reported a CB2 anti-obesity effect by silencing the activated immune cells in mice adipose tissue (), as well as a diet enriched with olive oil as responsible for increasing CB2 receptor expression in this tissue ().

Programming of the Endocannabinoid System During Early Life

The tonus of the ECS in the brain and peripheral tissues may be modulated by unappropriated parental life style and environmental conditions (nutrition, toxicant exposure, and stress) during the perinatal period and adolescence, predisposing offspring to metabolic and behavioral disorders throughout life (Figure 6,). This phenomenon is known as “metabolic programming” or “ontogenetic plasticity” and involves epigenetic regulation of gene expression ().

An external file that holds a picture, illustration, etc. Object name is fnins-15-747229-g006.jpg

Maternal environmental insults such as diet, smoking, and alcohol consumption during critical periods of life, as gestation, may affect the ECS in the hypothalamus-adipose axis of the mother and the progeny. The ECS disruption during early life can program metabolism in a short- and long-term way increasing the risk to develop metabolic syndrome and behavioral changes throughout life.

Maternal obesity/overweight and hypercaloric diet consumption are major concerns for metabolic programming. Two-thirds of American women at reproductive age are overweight, which represents a risk for their own health and the following generations ().

Maternal high-fat (45% fat) diet decreases serum levels of eCBs in baboon offspring at birth (). In rats, a maternal hypercaloric-low protein diet (6% protein, 24% fat) decreases hypothalamic endocannabinoid levels only in newborn male offspring, while decreases the preference for a chocolate diet and induces anxiety-like behavior in these animals in adulthood (). In a rat model, maternal isocaloric high-fat (29% fat) diet increases hypothalamic CB1 and CB2 expression in newborn male and female offspring, respectively, while increasing CB1 expression in BAT only in male offspring at birth (). In addition, maternal high-fat diet induces a differential regulation of CB1 content between visceral and subcutaneous WAT, suggesting redistribution of fat storages favoring visceral depot (). These ECS changes occurred in parallel to alteration of molecular markers of adipogenesis, lipogenesis, and thermogenesis across the adipose tissue depots of offspring at weaning (). Interestingly, there are sex-specific molecular signatures in the offspring at early life, but high-fat offspring of both sexes develop obesity, hyperphagia, and a higher preference for fat in adulthood ().

Of note, although many benefits of phytocannabinoids have been discussed in the context of neurodegenerative diseases and stress relief, the use of Cannabis during critical periods of development such as gestation and lactation as well as during adolescence may be harmful. Prenatal Cannabis exposure predicts fetal growth restriction, preterm delivery, and neonatal intensive care (). In human term placenta, THC increases AEA levels, which might be detrimental for the balance of trophoblast cells turnover leading to alterations in normal placentation and fetal growth (). In pregnant rats, Cannabis exposure reduces placental fetal capillary area and increases collagen deposition, these changes occur in parallel to reduced glucose transporter 1 expression in the labyrinth which may account for intrauterine growth restriction ().

Tetrahydrocannabinol crosses the placenta and binds to fetal CBs, changing neurodevelopment and possibly predisposing the offspring to abnormalities in cognition and emotion in humans and animal models (). In mice, THC exposure from embryonic day 12.5 to embryonic day 16.5, a critical window for corticospinal motor neuron development, results in a transient decrease in CB1 content and binding in whole embryonic brain that is rescued by postnatal day 2. These alterations are associated with increased seizure susceptibility in adult offspring (). Interestingly, embryonic THC exposure selectively decreases CB1 in the hippocampus of male mice at postnatal day 20 in parallel to decreased CB1-expressing GABA interneurons, resulting in impaired spatial memory in male adult mice (). In rats, maternal THC exposure from embryonic day 15 to postnatal day 9 decreases CB1 binding in the hippocampus and impairs GABAergic function in adult male offspring () associated with deficits in learning and memory ().

The adolescence is also an important vulnerable window of Cannabis exposure because adolescent brain is under relevant developmental plasticity. THC exposure in adolescent rats reduces CB1 content in the PFC and VTA at adulthood and, surprisingly, improves working memory performance in males (). Interestingly, male adult rats exposed to THC during 10 days in adolescence display increased self-administration of synthetic cannabinoid agonist associated with decreased dopamine levels in the NAc, suggesting addiction-like behavior that occurs in parallel to increased anxiety-like behavior ().

Epigenetic Regulation of the Endocannabinoid System

Epigenetics is strongly involved in the regulation of gene expression during early development and in response to psychological, metabolic, and nutritional influences to promote adaptation to environmental challenges throughout life. Epigenetic mechanisms are chemical modifications in the DNA or histones which alter chromatin status and gene transcription levels without changes in the nucleotide DNA sequence.

The main epigenetic marks are DNA methylation and histone acetylation. DNA methylation in the promoter region generally is associated with decreased transcription while histone acetylation shows an opposite fashion of regulation. Lifestyle features such as diet (), exercise (), stress (), pollutant exposure (), drug abuse (), and even perinatal environment () are known to modulate epigenome in humans and experimental models.

Epigenetics and ECS interplay regulating homeostasis from early embryogenesis to the point-by-point adjustments in adult life (). Interestingly, the genes encoding the main ECS components (Cnr1Cnr2Faah, and Mgll) are known to be physiologically regulated by epigenetic mechanisms and in response to diseases or environmental cues ().

Most of the studies are focused on the Cnr1 gene. Cnr1 contains two exons in the rat and four exons in humans without a classic CpG island (CpG dinucleotide frequency <60%) in the promoter. The methylation levels in the Cnr1 promoter are relatively high in peripheral tissues or cell types including human and rat colon cells (), and human peripheral blood cells (), with global promoter methylation ranging from 70 to 95%. In the brain, the Cnr1 methylation levels are low, as expected, ranging from 10 to 30% (). The inverse association between promoter methylation and Cnr1 mRNA levels is observed in several studies (). In humans, there is a progressive decrease in Cnr1 expression in the hippocampus and PFC from fetal to adult life, which is inversely associated with DNA methylation levels (). In rats, maternal high-fat diet during pregnancy increases the Cnr1 expression and histone acetylation of its distal promoter in the hypothalamus of male newborns (). In humans and animal models of schizophrenia, there are higher Crn1 mRNA levels in blood cells and PFC, respectively, which was associated with decreased methylation in the promoter (). Also, the expression of the Cnr1 gene increases in the PFC of patients with schizophrenia who completed suicide or were exposed to ethanol or THC (). Chronic stress in mice decreases the expression of Cnr1 in the cingulate cortex associated with reduced levels of histone acetylation (). CB1 activation by AEA is important to regulate the negative feedback and the basal activity of the HPA axis and, during stress, there is a decrease in AEA that may contribute to increased stress response and anxiety behavior ().

Sex Differences in the Central and Peripheral Endocannabinoid System in Health and Obesity

Body adiposity is under the regulation of both sex steroids and eCBs, and it is well known that males and females present specific fat distribution. While male subjects accumulate fat mainly in the intra-abdominal compartment, females are more likely to accumulate subcutaneous fat (). Fat distribution changes throughout life, especially after menopause when females undergo a profound decrease of ovarian hormones with fat redistribution favoring visceral accumulation ().

Interestingly, there are several pieces of evidence pointing to a mutual regulation between ECS and sex hormones in the CNS () and peripheral tissues such as the uterus (), gut (), and adipose tissue (). In healthy individuals, functional imaging studies have shown that males have more CB1 than females in several brain areas, including the PFC (), a region importantly involved in the hedonic response to palatable foods (). Additionally, females under treatment with combined oral contraceptives tend to present lower levels of CB1 compared to females with no contraceptives or during menopause, suggesting an inhibitory role of the estrogen levels on ECS ().

Studies in drugs of abuse have shown that women develop Cannabis addiction faster than men (), a phenomenon that has been confirmed also in experimental models of addiction (). Estradiol treatment in ovariectomized rats decreased CB1 receptor binding in the PFC (), evidencing an inverse relationship between estradiol levels and CB also in the rat brain. This association may explain, at least in part, lower CB1 binding in the brain of premenopausal women compared to male individuals.

Experimental studies have also shown that ECS is modulated in a sex-specific manner by several stressful events early in life. Adolescent female rats exposed to maternal deprivation in mid-lactation have increased levels of ECS components in the hippocampus while males exposed to the same insult have an increase of ECS in the PFC (). In a rat model of a maternal high-fat diet during gestation, male offspring have increased CB1 content in the hypothalamus at birth while female offspring had increased CB2 (), as mentioned before, highlighting the sex-specific effect of ECS modulation in the early origins of obesity. Adult female rats programmed by maternal high-fat diet early in life have increased CB1 content in WAT associated with decreased estradiol circulating levels, and a similar profile was observed in adipose tissue of ovariectomized adult rats ().

The crosstalk between ECS and sex steroid hormones is still reinforced by the characterization of estrogen or androgen response elements in the promoter of the genes encoding the ECS components, suggesting a direct interaction for transcriptional regulation (). Therefore, it is important to be aware that nutritional or pharmacological modulation of the ECS to improve health must consider different outcomes depending on sex.

Endocannabinoid System and Weight Loss

Modulation of the ECS in the CNS and peripheral tissues is an important strategy for weight loss (). Pharmacological CB1 antagonism reduces food intake and preference for palatable foods (rich in fat and sugar) by central mechanisms (). Also, CB1 antagonism decreases adiposity by a direct effect on white and brown adipocytes, where it reduces lipogenesis () and increases thermogenesis (), respectively. As known, the anti-obesity drug rimonabant (CB1 inverse agonist) entered in the market in 2006 showing great efficacy in reducing adiposity, leptin, and insulin resistance as well as improving glucose and lipid metabolism (). However, 2 years later, the drug was removed from the market due to relevant side effects as anxiety, depression, and suicidal ideation (). Therefore, there is a huge interest in the development of CB1 antagonism as a pharmacological tool for the treatment of metabolic disorders, with a better safety profile. In this sense, a study was performed in male C57BL/6 N mice undergoing auditory fear conditioning, followed by re-exposure to the tone with TM38837, largely peripherally restricted CB1 antagonist. Authors evaluated fear-promoting consequences of systemic vs. intracerebral injections and showed that TM38837 was at least one order of magnitude less effective in promoting fear responses than rimonabant. Given the equipotency of the two CB1 antagonists with regard to weight loss and metabolic syndrome-like symptoms in rodent obesity models, the results point to a critical dose range in which TM3887 might be beneficial for indications such as obesity and metabolic disorders with limited risk of fear-promoting effects ().

The impact of pharmacological modulation of CB2 on body weight regulation and metabolism is still controversial, but this receptor is involved in the inflammatory status of the WAT. The pharmacological CB2 antagonism improved adiposity and pro-inflammatory state in WAT and liver of obese mice (). On the other hand,  suggested that CB2 activation has anti-obesity effects, since the CB2 blockage increases fat store and reduces browning in human adipocytes. Furthermore, studies have reported a CB2 anti-obesity effect by silencing the activated immune cells in mice adipose tissue ().

Currently, there are no anti-obesity drugs based on the ECS in the market but pre-clinical studies suggest that CB1 pharmacological modulation using peripherally restrict molecules are promising (). Alternatively, non-pharmacological strategies of weight loss can also modulate the ECS avoiding the side effects in the CNS.

Caloric restriction is well known to be an important strategy for weight loss and improvement of metabolism. Recently, it was demonstrated that these beneficial effects involve a decrease in the circulating levels of AEA in type 2 diabetic patients which was strongly correlated with a decrease of the subcutaneous adipose tissue mass and, possibly, increased content of FAAH in adipose tissue (). Low AEA levels may result in attenuation of the ECS tonus in the CNS reducing hungry and in peripheral tissues attenuating lipogenesis and insulin resistance (). In contrast, the investigation of the ECS components in subcutaneous adipose tissue before and after weight loss in obese patients showed no effect on tissue levels of AEA and increased expression of Faah mRNA (). In a randomized controlled trial, healthy subjects underwent a 12-week moderate aerobic exercise program for weight loss and showed reduced levels of AEA which was associated with improvement in mood and anger (). Polymorphisms of the Faah gene have been associated with metabolic benefits after weight loss induced by a 3-month dietary intervention with a high-PUFA diet in obese subjects, such as a decrease in insulin resistance and leptinemia (), evidencing the important role of the endocannabinoid metabolism in metabolic health. Weight loss in morbid obesity (BMI > 40) is even more challenging and frequently requires a more invasive intervention, such as bariatric surgery. Interestingly, the weight loss and metabolic improvement observed in gastric bypass (RYGB) involve activation of the sympathetic tonus in the gut, which was associated with decreased CB1 and activation of WAT thermogenesis, a phenomenon known as “browning” that increases energy expenditure and resting metabolic rate (). Therefore, the modulation of the peripheral ECS (adipose tissue, gut, and liver) may also represent an important therapeutical target for bodyweight management.

Endocannabinoids and Inborn Errors of Metabolism

Inborn errors of metabolism (IEM) are genetic diseases caused by qualitative or quantitative deficiency of a specific protein. This protein may be an enzyme, transporter, receptor or else, and can affect different metabolic pathways. At present, more than 1,000 IEM have been described () and the majority significantly impact the quality of life of affected patients.

A few inborn errors of eCB metabolism have been described and can be associated with neurodegeneration (). Polyneuropathy, hearing loss, ataxia, retinitis pigmentosa, retinal degeneration and early-onset cataract, as well as cerebellar ataxia and slowly progressive polyneuropathy, are the main findings observed in a disease known as PHARC (). PHARC is an autosomal recessive disease caused by mutations in the α/β hydrolase domain-12 (ABHD12) gene, leading to increased 2-AG levels ().

Fatty acid amide hydrolase deficiency significantly increases AEA sensitivity and endocannabinoid signaling (). Individuals presenting mutations in the FAAH gene are more susceptible to drug and/or alcohol abuse (). Furthermore, inheritable deletions in the pseudogene FAAHP1, as found in pain sensitivity quantitative trait locus-1 (PAINQTL1), are associated with insensitivity to pain ().

Endocannabinoid system may also be implicated in the pathophysiology of other IEM. For instance, it has been suggested that endocannabinoid metabolism and signaling are impaired in several lysosomal storage diseases (LSD) (). Studies using animal models of Niemann-Pick disease type A and B (acid sphingomyelinase deficiency) showed that CB1 receptors are downregulated on the surface of neurons probably due to entrapment of the receptor within lysosomes (). Niemann-Pick disease type C is a potentially fatal LSD caused by mutations of NPC1 or NPC2 gene, impairing cholesterol homeostasis (). Membrane cholesterol plays a pivotal role in the ECS regulation (). This neurotransmitter system has been shown to be defective in animal models of Niemann-Pick disease type C (), contributing to the neurodegeneration observed in patients (). CB2 receptors were shown to be altered in animal models of mucopolysaccharidosis type IIIA and of acid ceramidase deficiency (Farber’s disease) (). In both diseases the overexpression of CB2 found in many tissues are probably related to the neuroinflammation observed in these animals ().

Organic acidurias are IEM characterized by the accumulation of one or more organic acids in tissue and body fluids of patients, with significantly brain function impairment (). Glutaric aciduria type I, methylmalonic aciduria and propionic aciduria are organic acidurias in which neurodegeneration is related to different pathophysiological mechanisms including oxidative stress, impairment of bioenergetics, and neurotransmitter systems (). In vitro experiments showed that WIN55,212-2 protects from neurotoxicity elicited by organic acids accumulating in glutaric aciduria type I, methylmalonic aciduria and propionic aciduria. This protective effect was attributed to a possible ECS imbalance in the pathophysiology of organic acidurias ().

Author Contributions

All authors listed have made a substantial, direct and intellectual contribution to the work, and approved it for publication.

Conflict of Interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Abbreviations

ALA alpha linolenic acid
ALEA alpha-linolenoylethanolamide
AD Alzheimer’s disease
CBD cannabidiol
CB1 cannabinoid receptor type 1
CB2 cannabinoid receptor type 2
ECS endocannabinoid system
CNS central nervous system
anandamide or AEA N-arachidonoylethanolamide
2-AG 2-arachidonoylglycerol
LC-PUFAs long chain polyunsaturated fatty acids
MAPK mitogen-activated protein kinase
OEA O-arachidonoylethanolamide
THC tetrahydrocannabinol
HP hemopressin
FAAH fatty acid amide hydrolase
PNS peripheral nervous system
GM gray matter
HPA hypothalamic-pituitary-adrenal
eCB endocannabinoid
PEA palmitoyl-ethanolamide
PD Parkinson’s disease
DHEA N-docosahexaenoyl -ethanolamine
EPEA N-eicosapentaenoyl -ethanolamine
2-DHG 2-docosahexaenoylglycerol
EPG 2-eicosapentaenoylglycerol
EEQ-EA epoxyeicosatetraenoic acid-ethanolamide
EDP-EA epoxydocosapentaenoic acid-ethanolamide
PA physical activity
AA Arachidonic acid.

Funding

AI and HF were recipients of a postdoc fellowship supported by CNPq (HRF grant number 152071/2020-2). MMA was a recipient of a postdoc fellowship supported by FAPERJ (Grant Number E-26/202.029/2020). PS was supported by CNPq. GF was supported by CNPq (PQ Grant Number 309849/2018-7) and FAPERJ (JCNE Grant Number E-26/202.808/2019). RM was supported by FAPERJ (Grant Numbers E-26/202.668/2018, E-26/010.002215/2019, 426342/2018-6, and 312157/2016-9) and INCT-INNT (National Institute for Translational Neuroscience). BA-d-C was supported by CAPES (Coordination for higher Education Staff Development), PROCAD-2013 and Finance Code 001; FACEPE (Foundation for Research Support of the State of Pernambuco): Grant Number APQ 1037—2.07/15), FAPERJ (Carlos Chagas Filho Foundation for Research Support of the State of Rio de Janeiro), and CNPq (National Council for Scientific and Technological Development).

References

  • Abel E. L. (1975). Cannabis: effects on hunger and thirst. Behav. Biol. 15 255–281. [PubMed[]
  • Ahmad R., Goffin K., Van Den Stock J., De Winter F. L., Cleeren E., Bormans G., et al. (2014). In vivo type 1 cannabinoid receptor availability in Alzheimer’s disease. Eur. Neuropsychopharmacol. 24 242–250. [PubMed[]
  • Alayoubi A. M., Wang J. C., Au B. C., Carpentier S., Garcia V., Dworski S., et al. (2013). Systemic ceramide accumulation leads to severe and varied pathological consequences. EMBO Mol. Med. 5 827–842. 10.1002/emmm.201202301 [PMC free article] [PubMed] [CrossRef[]
  • Almeida M. M., Dias-Rocha C. P., Reis-Gomes C. F., Wang H., Atella G. C., Cordeiro A., et al. (2019). Maternal high-fat diet impairs leptin signaling and up-regulates type-1 cannabinoid receptor with sex-specific epigenetic changes in the hypothalamus of newborn rats. Psychoneuroendocrinology 103 306–315. 10.1016/j.psyneuen.2019.02.004 [PubMed] [CrossRef[]
  • Almeida M. M., Dias-Rocha C. P., Reis-Gomes C. F., Wang H., Cordeiro A., Pazos-Moura C. C., et al. (2020). Maternal high-fat diet up-regulates type-1 cannabinoid receptor with estrogen signaling changes in a sex- and depot- specific manner in white adipose tissue of adult rat offspring. Eur. J. Nutr. 60 1313–1326. [PubMed[]
  • Almeida M. M., Dias-Rocha C. P., Souza A. S., Muros M. F., Mendonca L. S., Pazos-Moura C. C., et al. (2017). Perinatal maternal high-fat diet induces early obesity and sex-specific alterations of the endocannabinoid system in white and brown adipose tissue of weanling rat offspring. Br. J. Nutr. 118 788–803. 10.1017/S0007114517002884 [PubMed] [CrossRef[]
  • Alpár A., Di Marzo V., Harkany T. (2016). At the tip of an iceberg: prenatal marijuana and its possible relation to neuropsychiatric outcome in the offspring. Biol. Psychiatry 79 e33–e45. 10.1016/j.biopsych.2015.09.009 [PubMed] [CrossRef[]
  • Alteba S., Korem N., Akirav I. (2016). Cannabinoids reverse the effects of early stress on neurocognitive performance in adulthood. Learn. Mem. 23 349–358. 10.1101/lm.041608.116 [PMC free article] [PubMed] [CrossRef[]
  • Andrade-da-Costa B. L. D. S., Isaac A. R., Augusto R. L., De Souza R. F., Freitas H. R., De Melo Reis R. A. (2019). “Epigenetic effects of omega-3 fatty acids on neurons and astrocytes during brain development and senescence,” in Omega Fatty Acids in Brain and Neurological Health, eds Watson R. R., Preedy V. R. (Cambridge, MA: Academic Press; ), 479–490. []
  • Arida R. M., Gomes Da Silva S., De Almeida A. A., Cavalheiro E. A., Zavala-Tecuapetla C., Brand S., et al. (2015). Differential effects of exercise on brain opioid receptor binding and activation in rats. J. Neurochem. 132 206–217. [PubMed[]
  • Ashton C. H. (2001). Pharmacology and effects of cannabis: a brief review. Br. J. Psychiatry 178 101–106. [PubMed[]
  • Aso E., Palomer E., Juvés S., Maldonado R., Muñoz F. J., Ferrer I. (2012). CB1 agonist ACEA protects neurons and reduces the cognitive impairment of AβPP/PS1 mice. J. Alzheimers Dis. 30 439–459. 10.3233/JAD-2012-111862 [PubMed] [CrossRef[]
  • Aso E., Sánchez-Pla A., Vegas-Lozano E., Maldonado R., Ferrer I. (2015). Cannabis-based medicine reduces multiple pathological processes in AβPP/PS1 mice. J. Alzheimers Dis. 43 977–991. 10.3233/JAD-141014 [PubMed] [CrossRef[]
  • Assis L. C., Straliotto M. R., Engel D., Hort M. A., Dutra R. C., De Bem A. F. (2014). β-Caryophyllene protects the C6 glioma cells against glutamate-induced excitotoxicity through the Nrf2 pathway. Neuroscience 279 220–231. 10.1016/j.neuroscience.2014.08.043 [PubMed] [CrossRef[]
  • Assmann K. E., Adjibade M., Shivappa N., Hébert J. R., Wirth M. D., Touvier M., et al. (2018). The inflammatory potential of the diet at midlife is associated with later healthy aging in French adults. J. Nutr. 148 437–444. 10.1093/jn/nxx061 [PMC free article] [PubMed] [CrossRef[]
  • Babson K. A., Sottile J., Morabito D. (2017). Cannabis, cannabinoids, and sleep: a review of the literature. Curr. Psychiatry Rep. 19:23. [PubMed[]
  • Bahi A., Al Mansouri S., Al Memari E., Al Ameri M., Nurulain S. M., Ojha S. (2014). β-Caryophyllene, a CB2 receptor agonist produces multiple behavioral changes relevant to anxiety and depression in mice. Physiol. Behav. 135 119–124. 10.1016/j.physbeh.2014.06.003 [PubMed] [CrossRef[]
  • Banni S., Di Marzo V. (2010). Effect of dietary fat on endocannabinoids and related mediators: consequences on energy homeostasis, inflammation and mood. Mol. Nutr. Food Res. 54 82–92. 10.1002/mnfr.200900516 [PubMed] [CrossRef[]
  • Bara A., Ferland J. N., Rompala G., Szutorisz H., Hurd Y. L. (2021). Cannabis and synaptic reprogramming of the developing brain. Nat. Rev. Neurosci. 22 423–438. 10.1038/s41583-021-00465-5 [PMC free article] [PubMed] [CrossRef[]
  • Barna I., Zelena D., Arszovszki A. C., Ledent C. (2004). The role of endogenous cannabinoids in the hypothalamo-pituitary-adrenal axis regulation: in vivo and in vitro studies in CB1 receptor knockout mice. Life Sci. 75 2959–2970. 10.1016/j.lfs.2004.06.006 [PubMed] [CrossRef[]
  • Bartoll A., Toledano-Zaragoza A., Casas J., Guzmán M., Schuchman E. H., Ledesma M. D. (2020). Inhibition of fatty acid amide hydrolase prevents pathology in neurovisceral acid sphingomyelinase deficiency by rescuing defective endocannabinoid signaling. EMBO Mol. Med. 12:e11776. 10.15252/emmm.201911776 [PMC free article] [PubMed] [CrossRef[]
  • Batetta B., Griinari M., Carta G., Murru E., Ligresti A., Cordeddu L., et al. (2009). Endocannabinoids may mediate the ability of (n-3) fatty acids to reduce ectopic fat and inflammatory mediators in obese Zucker rats. J. Nutr. 139 1495–1501. 10.3945/jn.109.104844 [PubMed] [CrossRef[]
  • Battistella G., Fornari E., Annoni J. M., Chtioui H., Dao K., Fabritius M., et al. (2014). Long-term effects of cannabis on brain structure. Neuropsychopharmacology 39 2041–2048. 10.1038/npp.2014.67 [PMC free article] [PubMed] [CrossRef[]
  • Bedse G., Romano A., Cianci S., Lavecchia A. M., Lorenzo P., Elphick M. R., et al. (2014). Altered expression of the CB1 cannabinoid receptor in the triple transgenic mouse model of Alzheimer’s disease. J. Alzheimers Dis. 40 701–712. 10.3233/JAD-131910 [PubMed] [CrossRef[]
  • Beggiato S., Borelli A. C., Tomasini M. C., Morgano L., Antonelli T., Tanganelli S., et al. (2017). Long-lasting alterations of hippocampal GABAergic neurotransmission in adult rats following perinatal Delta(9)-THC exposure. Neurobiol. Learn. Mem. 139 135–143. 10.1016/j.nlm.2016.12.023 [PubMed] [CrossRef[]
  • Behan C. (2020). The benefits of meditation and mindfulness practices during times of crisis such as COVID-19. Irish J. Psychol. Med. 37 256–258. 10.1017/ipm.2020.38 [PMC free article] [PubMed] [CrossRef[]
  • Beins E. C., Beiert T., Jenniches I., Hansen J. N., Leidmaa E., Schrickel J. W., et al. (2021). Cannabinoid receptor 1 signalling modulates stress susceptibility and microglial responses to chronic social defeat stress. Transl. Psychiatry 11:164. 10.1038/s41398-021-01283-0 [PMC free article] [PubMed] [CrossRef[]
  • Belenguer P., Duarte J. M. N., Schuck P. F., Ferreira G. C. (2019). Mitochondria and the brain: bioenergetics and beyond. Neurotox Res. 36 219–238. [PubMed[]
  • Belitardo de Oliveira A., De Mello M. T., Tufik S., Peres M. F. P. (2019). Weight loss and improved mood after aerobic exercise training are linked to lower plasma anandamide in healthy people. Physiol. Behav. 201 191–197. 10.1016/j.physbeh.2018.12.018 [PubMed] [CrossRef[]
  • Bénard G., Massa F., Puente N., Lourenço J., Bellocchio L., Soria-Gómez E., et al. (2012). Mitochondrial CB1 receptors regulate neuronal energy metabolism. Nat. Neurosci. 15 558–564. [PubMed[]
  • Benarroch E. (2007). Endocannabinoids in basal ganglia circuits: implications for Parkinson disease. Neurology 69 306–309. [PubMed[]
  • Benito C., Núñez E., Tolón R. M., Carrier E. J., Rábano A., Hillard C. J., et al. (2003). Cannabinoid CB2 receptors and fatty acid amide hydrolase are selectively overexpressed in neuritic plaque-associated glia in Alzheimer’s disease brains. J. Neurosci. 23 11136–11141. 10.1523/JNEUROSCI.23-35-11136.2003 [PMC free article] [PubMed] [CrossRef[]
  • Bennett G., Young E., Butler I., Coe S. (2021). The impact of lockdown during the COVID-19 outbreak on dietary habits in various population groups: a scoping review. Front. Nutr. 8:626432. 10.3389/fnut.2021.626432 [PMC free article] [PubMed] [CrossRef[]
  • Bennetzen M. F., Nielsen T. S., Paulsen S. K., Bendix J., Fisker S., Jessen N., et al. (2010). Reduced cannabinoid receptor 1 protein in subcutaneous adipose tissue of obese. Eur. J. Clin. Invest. 40 121–126. [PubMed[]
  • Bennetzen M. F., Wellner N., Ahmed S. S., Ahmed S. M., Diep T. A., Hansen H. S., et al. (2011). Investigations of the human endocannabinoid system in two subcutaneous adipose tissue depots in lean subjects and in obese subjects before and after weight loss. Int. J. Obes. 35 1377–1384. 10.1038/ijo.2011.8 [PubMed] [CrossRef[]
  • Berge K., Piscitelli F., Hoem N., Silvestri C., Meyer I., Banni S., et al. (2013). Chronic treatment with krill powder reduces plasma triglyceride and anandamide levels in mildly obese men. Lipids Health Dis. 12:78. 10.1186/1476-511X-12-78 [PMC free article] [PubMed] [CrossRef[]
  • Bermudez-Siva F. J., Serrano A., Diaz-Molina F. J., Sanchez Vera I., Juan-Pico P., Nadal A., et al. (2006). Activation of cannabinoid CB1 receptors induces glucose intolerance in rats. Eur. J. Pharmacol. 531 282–284. [PubMed[]
  • Bhaumik M., Muller V. J., Rozaklis T., Johnson L., Dobrenis K., Bhattacharyya R., et al. (1999). A mouse model for mucopolysaccharidosis type III A (Sanfilippo syndrome). Glycobiology 9 1389–1396. [PubMed[]
  • Bisogno T., Maccarrone M. (2014). Endocannabinoid signaling and its regulation by nutrients. Biofactors 40 373–380. [PubMed[]
  • Blesching U. (2020). Your Cannabis CBD:THC Ratio: A Guide to Precision Dosing for Health and Wellness. Quick Trading Company. []
  • Boon M. R., Kooijman S., Van Dam A. D., Pelgrom L. R., Berbee J. F., Visseren C. A., et al. (2014). Peripheral cannabinoid 1 receptor blockade activates brown adipose tissue and diminishes dyslipidemia and obesity. FASEB J. 28 5361–5375. 10.1096/fj.13-247643 [PubMed] [CrossRef[]
  • Bouret S. G., Draper S. J., Simerly R. B. (2004). Trophic action of leptin on hypothalamic neurons that regulate feeding. Science 304 108–110. [PubMed[]
  • Brenseke B., Prater M. R., Bahamonde J., Gutierrez J. C. (2013). Current thoughts on maternal nutrition and fetal programming of the metabolic syndrome. J. Pregnancy 2013:368461. 10.1155/2013/368461 [PMC free article] [PubMed] [CrossRef[]
  • Bridgeman M. B., Abazia D. T. (2017). Medicinal cannabis: history, pharmacology, and implications for the acute care setting. P & T 42 180–188. [PMC free article] [PubMed[]
  • Broers B., Patà Z., Mina A., Wampfler J., De saussure C., Pautex S. (2019). Prescription of a THC/CBD-based medication to patients with dementia: a pilot study in Geneva. Med. Cannabis Cannabinoids 2 56–59. [PMC free article] [PubMed[]
  • Brook R. D., Appel L. J., Rubenfire M., Ogedegbe G., Bisognano J. D., Elliott W. J., et al. (2013). Beyond medications and diet: alternative approaches to lowering blood pressure. Hypertension 61 1360–1383. [PubMed[]
  • Bühlmayer L., Birrer D., Röthlin P., Faude O., Donath L. (2017). Effects of mindfulness practice on performance-relevant parameters and performance outcomes in sports: a meta-analytical review. Sports Med. 47 2309–2321. 10.1007/s40279-017-0752-9 [PubMed] [CrossRef[]
  • Burbridge S., Stewart I., Placzek M. (2016). Development of the neuroendocrine hypothalamus. Compr. Physiol. 6 623–643. [PubMed[]
  • Burgio E., Lopomo A., Migliore L. (2015). Obesity and diabetes: from genetics to epigenetics. Mol. Biol. Rep. 42 799–818. [PubMed[]
  • Cahn B. R., Goodman M. S., Peterson C. T., Maturi R., Mills P. J. (2017). Yoga, meditation and mind-body health: increased BDNF, cortisol awakening response, and altered inflammatory marker expression after a 3-month yoga and meditation retreat. Front. Hum. Neurosci. 11:315. 10.3389/fnhum.2017.00315 [PMC free article] [PubMed] [CrossRef[]
  • Calderon-Garciduenas L., Herrera-Soto A., Jury N., Maher B. A., Gonzalez-Maciel A., Reynoso-Robles R., et al. (2020). Reduced repressive epigenetic marks, increased DNA damage and Alzheimer’s disease hallmarks in the brain of humans and mice exposed to particulate urban air pollution. Environ. Res. 183:109226. 10.1016/j.envres.2020.109226 [PubMed] [CrossRef[]
  • Camille Melon L., Maguire J. (2016). GABAergic regulation of the HPA and HPG axes and the impact of stress on reproductive function. J. Steroid Biochem. Mol. Biol. 160 196–203. 10.1016/j.jsbmb.2015.11.019 [PMC free article] [PubMed] [CrossRef[]
  • Campolongo P., Trezza V., Cassano T., Gaetani S., Morgese M. G., Ubaldi M., et al. (2007). Perinatal exposure to delta-9-tetrahydrocannabinol causes enduring cognitive deficits associated with alteration of cortical gene expression and neurotransmission in rats. Addict. Biol. 12 485–495. 10.1111/j.1369-1600.2007.00074.x [PubMed] [CrossRef[]
  • Campos A. C., Fogaça M. V., Sonego A. B., Guimarães F. S. (2016). Cannabidiol, neuroprotection and neuropsychiatric disorders. Pharmacol. Res. 112 119–127. [PubMed[]
  • Cao-Lei L., Elgbeili G., Szyf M., Laplante D. P., King S. (2019). Differential genome-wide DNA methylation patterns in childhood obesity. BMC Res. Notes 12:174. 10.1186/s13104-019-4189-0 [PMC free article] [PubMed] [CrossRef[]
  • Castelli M. P., Fadda P., Casu A., Spano M. S., Casti A., Fratta W., et al. (2014). Male and female rats differ in brain cannabinoid CB1 receptor density and function and in behavioural traits predisposing to drug addiction: effect of ovarian hormones. Curr. Pharm. Des. 20 2100–2113. 10.2174/13816128113199990430 [PubMed] [CrossRef[]
  • Celorrio M., Fernández-Suárez D., Rojo-Bustamante E., Echeverry-Alzate V., Ramírez M. J., Hillard C. J., et al. (2016). Fatty acid amide hydrolase inhibition for the symptomatic relief of Parkinson’s disease. Brain Behav. Immun. 57 94–105. 10.1016/j.bbi.2016.06.010 [PubMed] [CrossRef[]
  • Chagas M. H., Zuardi A. W., Tumas V., Pena-Pereira M. A., Sobreira E. T., Bergamaschi M. M., et al. (2014). Effects of cannabidiol in the treatment of patients with Parkinson’s disease: an exploratory double-blind trial. J. Psychopharmacol. 28 1088–1098. 10.1177/0269881114550355 [PubMed] [CrossRef[]
  • Chen P., Zhang Q., Zhang H., Gao Y., Zhou Y., Chen Y., et al. (2021). Carnitine palmitoyltransferase 1C reverses cellular senescence of MRC-5 fibroblasts via regulating lipid accumulation and mitochondrial function. J. Cell. Physiol. 236 958–970. 10.1002/jcp.29906 [PubMed] [CrossRef[]
  • Cheng D., Spiro A. S., Jenner A. M., Garner B., Karl T. (2014). Long-term cannabidiol treatment prevents the development of social recognition memory deficits in Alzheimer’s disease transgenic mice. J. Alzheimers Dis. 42 1383–1396. 10.3233/JAD-140921 [PubMed] [CrossRef[]
  • Cheng Y., Dong Z., Liu S. (2014). β-Caryophyllene ameliorates the Alzheimer-like phenotype in APP/PS1 Mice through CB2 receptor activation and the PPARγ pathway. Pharmacology 94 1–12. 10.1159/000362689 [PubMed] [CrossRef[]
  • Chiurchiu V., Lanuti M., Catanzaro G., Fezza F., Rapino C., Maccarrone M. (2014). Detailed characterization of the endocannabinoid system in human macrophages and foam cells, and anti-inflammatory role of type-2 cannabinoid receptor. Atherosclerosis 233 55–63. 10.1016/j.atherosclerosis.2013.12.042 [PubMed] [CrossRef[]
  • Choi I. Y., Ju C., Anthony Jalin A. M., Lee D. I., Prather P. L., Kim W. K. (2013). Activation of cannabinoid CB2 receptor-mediated AMPK/CREB pathway reduces cerebral ischemic injury. Am. J. Pathol. 182 928–939. 10.1016/j.ajpath.2012.11.024 [PubMed] [CrossRef[]
  • Choi S., Huang B. C., Gamaldo C. E. (2020). Therapeutic uses of cannabis on sleep disorders and related conditions. J. Clin. Neurophysiol. 37 39–49. [PubMed[]
  • Christensen R., Kristensen P. K., Bartels E. M., Bliddal H., Astrup A. (2007). Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials. Lancet 370 1706–1713. [PubMed[]
  • Coccurello R., Maccarrone M. (2018). Hedonic eating and the “delicious circle”: from lipid-derived mediators to brain dopamine and back. Front. Neurosci. 12:271. 10.3389/fnins.2018.00271 [PMC free article] [PubMed] [CrossRef[]
  • Colín-González A. L., Paz-Loyola A. L., Serratos I. N., Seminotti B., Ribeiro C. A., Leipnitz G., et al. (2015). The effect of WIN 55,212-2 suggests a cannabinoid-sensitive component in the early toxicity induced by organic acids accumulating in glutaric acidemia type I and in related disorders of propionate metabolism in rat brain synaptosomes. Neuroscience 310 578–588. 10.1016/j.neuroscience.2015.09.043 [PubMed] [CrossRef[]
  • Concannon R. M., Okine B. N., Finn D. P., Dowd E. (2015). Differential upregulation of the cannabinoid CB2 receptor in neurotoxic and inflammation-driven rat models of Parkinson’s disease. Exp. Neurol. 269 133–141. 10.1016/j.expneurol.2015.04.007 [PubMed] [CrossRef[]
  • Contrepois K., Wu S., Moneghetti K. J., Hornburg D., Ahadi S., Tsai M.-S., et al. (2020). Molecular choreography of acute exercise. Cell 181 1112–1130.e16. [PMC free article] [PubMed[]
  • Cooper Z. D., Haney M. (2014). Investigation of sex-dependent effects of cannabis in daily cannabis smokers. Drug Alcohol Depend. 136 85–91. 10.1016/j.drugalcdep.2013.12.013 [PMC free article] [PubMed] [CrossRef[]
  • Cotrim B. A., Joglar J., Rojas M. J., Del Olmo J. M., Macias-González M., Cuevas M. R., et al. (2012). Unsaturated fatty alcohol derivatives of olive oil phenolic compounds with potential low-density lipoprotein (LDL) antioxidant and antiobesity properties. J. Agric. Food Chem. 60 1067–1074. 10.1021/jf203814r [PubMed] [CrossRef[]
  • Cramer H., Lauche R., Langhorst J., Dobos G. (2013). Yoga for depression: a systematic review and meta-analysis. Depress. Anxiety 30 1068–1083. [PubMed[]
  • Cravatt B. F., Demarest K., Patricelli M. P., Bracey M. H., Giang D. K., Martin B. R., et al. (2001). Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase. Proc. Natl. Acad. Sci. U.S.A. 98 9371–9376. 10.1073/pnas.161191698 [PMC free article] [PubMed] [CrossRef[]
  • Crean R. D., Crane N. A., Mason B. J. (2011). An evidence based review of acute and long-term effects of cannabis use on executive cognitive functions. J. Addict. Med. 5 1–8. [PMC free article] [PubMed[]
  • Cristino L., Bisogno T., Di Marzo V. (2020). Cannabinoids and the expanded endocannabinoid system in neurological disorders. Nat. Rev. Neurol. 16 9–29. [PubMed[]
  • Cristino L., Busetto G., Imperatore R., Ferrandino I., Palomba L., Silvestri C., et al. (2013). Obesity-driven synaptic remodeling affects endocannabinoid control of orexinergic neurons. Proc. Natl. Acad. Sci. U.S.A. 110 E2229–E2238. 10.1073/pnas.1219485110 [PMC free article] [PubMed] [CrossRef[]
  • Crombie K. M., Sartin-Tarm A., Sellnow K., Ahrenholtz R., Lee S., Matalamaki M., et al. (2021). Exercise-induced increases in Anandamide and BDNF during extinction consolidation contribute to reduced threat following reinstatement: preliminary evidence from a randomized controlled trial. Psychoneuroendocrinology 132:105355. 10.1016/j.psyneuen.2021.105355 [PMC free article] [PubMed] [CrossRef[]
  • Cruz-Martinez A. M., Tejas-Juarez J. G., Mancilla-Diaz J. M., Floran-Garduno B., Lopez-Alonso V. E., Escartin-Perez R. E. (2018). CB1 receptors in the paraventricular nucleus of the hypothalamus modulate the release of 5-HT and GABA to stimulate food intake in rats. Eur. Neuropsychopharmacol. 28 1247–1259. 10.1016/j.euroneuro.2018.08.002 [PubMed] [CrossRef[]
  • Cunha J. M., Carlini E. A., Pereira A. E., Ramos O. L., Pimentel C., Gagliardi R., et al. (1980). Chronic administration of cannabidiol to healthy volunteers and epileptic patients. Pharmacology 21 175–185. [PubMed[]
  • Cusick S. E., Georgieff M. K. (2016). The role of nutrition in brain development: the golden opportunity of the “first 1000 days”. J. Pediatr. 175 16–21. 10.1016/j.jpeds.2016.05.013 [PMC free article] [PubMed] [CrossRef[]
  • Cuttler C., Spradlin A., Cleveland M. J., Craft R. M. (2020). Short- and long-term effects of cannabis on headache and migraine. J. Pain 21 722–730. 10.1016/j.jpain.2019.11.001 [PubMed] [CrossRef[]
  • D’Addario C., Micale V., Di Bartolomeo M., Stark T., Pucci M., Sulcova A., et al. (2017). A preliminary study of endocannabinoid system regulation in psychosis: distinct alterations of CNR1 promoter DNA methylation in patients with schizophrenia. Schizophr. Res. 188 132–140. 10.1016/j.schres.2017.01.022 [PubMed] [CrossRef[]
  • D’Addario C., Micioni Di Bonaventura M. V., Pucci M., Romano A., Gaetani S., Ciccocioppo R., et al. (2014). Endocannabinoid signaling and food addiction. Neurosci. Biobehav. Rev. 47 203–224. [PubMed[]
  • Dainese E., Oddi S., Maccarrone M. (2010). Interaction of endocannabinoid receptors with biological membranes. Curr. Med. Chem. 17 1487–1499. [PubMed[]
  • D’Angelo S., Motti M. L., Meccariello R. (2020). ω-3 and ω-6 polyunsaturated fatty acids, obesity and cancer. Nutrients 12:2751. 10.3390/nu12092751 [PMC free article] [PubMed] [CrossRef[]
  • Danhauer S. C., Addington E. L., Sohl S. J., Chaoul A., Cohen L. (2017). Review of yoga therapy during cancer treatment. Support Care Cancer 25 1357–1372. [PMC free article] [PubMed[]
  • Darlington D. N., Miyamoto M., Keil L. C., Dallman M. F. (1989). Paraventricular stimulation with glutamate elicits bradycardia and pituitary responses. Am. J. Physiol. 256 R112–R119. 10.1152/ajpregu.1989.256.1.R112 [PubMed] [CrossRef[]
  • Dauer W., Przedborski S. (2003). Parkinson’s disease: mechanisms and models. Neuron 39 889–909. [PubMed[]
  • de Almeida M. M., Dias-Rocha C. P., Reis-Gomes C. F., Wang H., Cordeiro A., Pazos-Moura C. C., et al. (2021). Maternal high-fat diet up-regulates type-1 cannabinoid receptor with estrogen signaling changes in a sex- and depot- specific manner in white adipose tissue of adult rat offspring. Eur. J. Nutr. 60 1313–1326. 10.1007/s00394-020-02318-w [PubMed] [CrossRef[]
  • de Aquino C. C., Leitão R. A., Oliveira Alves L. A., Coelho-Santos V., Guerrant R. L., Ribeiro C. F., et al. (2019). Effect of hypoproteic and high-fat diets on hippocampal blood-brain barrier permeability and oxidative stress. Front. Nutr. 5:131. 10.3389/fnut.2018.00131 [PMC free article] [PubMed] [CrossRef[]
  • De Genna N. M., Goldschmidt L., Richardson G. A., Cornelius M. D., Day N. L. (2021). Prenatal exposure to tobacco and cannabis, early cannabis initiation, and daily dual use of combustible cigarettes and cannabis during young adulthood. Addict. Behav. 116:106820. 10.1016/j.addbeh.2021.106820 [PMC free article] [PubMed] [CrossRef[]
  • de Luis D. A., Izaola O., Aller R., De La Fuente B., Pacheco D. (2013). Effects of C358A polymorphism of the endocannabinoid degrading enzyme fatty acid amide hydrolase (FAAH) on weight loss, adipocytokines levels, and insulin resistance after a high polyunsaturated fat diet in obese patients. J. Endocrinol. Invest. 36 965–969. 10.1007/BF03346760 [PubMed] [CrossRef[]
  • de Oliveira E., Quitete F. T., Bernardino D. N., Guarda D. S., Caramez F. A. H., Soares P. N., et al. (2019). Maternal coconut oil intake on lactation programs for endocannabinoid system dysfunction in adult offspring. Food Chem. Toxicol. 130 12–21. 10.1016/j.fct.2019.05.002 [PubMed] [CrossRef[]
  • De Petrocellis L., Cascio M. G., Di Marzo V. (2004). The endocannabinoid system: a general view and latest additions. Br. J. Pharmacol. 141 765–774. 10.1038/sj.bjp.0705666 [PMC free article] [PubMed] [CrossRef[]
  • de Salas-Quiroga A., Diaz-Alonso J., Garcia-Rincon D., Remmers F., Vega D., Gomez-Canas M., et al. (2015). Prenatal exposure to cannabinoids evokes long-lasting functional alterations by targeting CB1 receptors on developing cortical neurons. Proc. Natl. Acad. Sci. U.S.A. 112 13693–13698. 10.1073/pnas.1514962112 [PMC free article] [PubMed] [CrossRef[]
  • de Salas-Quiroga A., Garcia-Rincon D., Gomez-Dominguez D., Valero M., Simon-Sanchez S., Paraiso-Luna J., et al. (2020). Long-term hippocampal interneuronopathy drives sex-dimorphic spatial memory impairment induced by prenatal THC exposure. Neuropsychopharmacology 45 877–886. 10.1038/s41386-020-0621-3 [PMC free article] [PubMed] [CrossRef[]
  • Deahl M. (1991). Cannabis and memory loss. Br. J. Addict. 86 249–252. [PubMed[]
  • Demirakca T., Sartorius A., Ende G., Meyer N., Welzel H., Skopp G., et al. (2011). Diminished gray matter in the hippocampus of cannabis users: possible protective effects of cannabidiol. Drug Alcohol Depend. 114 242–245. 10.1016/j.drugalcdep.2010.09.020 [PubMed] [CrossRef[]
  • Deveaux V., Cadoudal T., Ichigotani Y., Teixeira-Clerc F., Louvet A., Manin S., et al. (2009). Cannabinoid CB2 receptor potentiates obesity-associated inflammation, insulin resistance and hepatic steatosis. PLoS One 4:e5844. 10.1371/journal.pone.0005844 [PMC free article] [PubMed] [CrossRef[]
  • Devine M. J., Kittler J. T. (2018). Mitochondria at the neuronal presynapse in health and disease. Nat. Rev. Neurosci. 19 63–80. 10.1038/nrn.2017.170 [PubMed] [CrossRef[]
  • Di Bartolomeo M., Stark T., Maurel O. M., Iannotti F. A., Kuchar M., Ruda-Kucerova J., et al. (2021). Crosstalk between the transcriptional regulation of dopamine D2 and cannabinoid CB1 receptors in schizophrenia: analyses in patients and in perinatal Δ9-tetrahydrocannabinol-exposed rats. Pharmacol. Res. 164:105357. 10.1016/j.phrs.2020.105357 [PubMed] [CrossRef[]
  • Di Francesco A., Falconi A., Di Germanio C., Micioni Di Bonaventura M. V., Costa A., Caramuta S., et al. (2015). Extravirgin olive oil up-regulates CB(1) tumor suppressor gene in human colon cancer cells and in rat colon via epigenetic mechanisms. J. Nutr. Biochem. 26 250–258. 10.1016/j.jnutbio.2014.10.013 [PubMed] [CrossRef[]
  • Di Liegro C. M., Schiera G., Proia P., Di Liegro I. (2019). Physical activity and brain health. Genes 10:720[]
  • Di Marzo V. (1998). ‘Endocannabinoids’ and other fatty acid derivatives with cannabimimetic properties: biochemistry and possible physiopathological relevance. Biochim. Biophys. Acta 1392 153–175. 10.1016/s0005-2760(98)00042-3 [PubMed] [CrossRef[]
  • Di Marzo V., Piscitelli F. (2015). The endocannabinoid system and its modulation by phytocannabinoids. Neurotherapeutics 12 692–698. [PMC free article] [PubMed[]
  • Dias-Rocha C. P., Almeida M. M., Santana E. M., Costa J. C. B., Franco J. G., Pazos-Moura C. C., et al. (2018). Maternal high-fat diet induces sex-specific endocannabinoid system changes in newborn rats and programs adiposity, energy expenditure and food preference in adulthood. J. Nutr. Biochem. 51 56–68. 10.1016/j.jnutbio.2017.09.019 [PubMed] [CrossRef[]
  • Dienel G. A. (2019). Brain glucose metabolism: integration of energetics with function. Physiol. Rev. 99 949–1045. [PubMed[]
  • Docter S., Khan M., Gohal C., Ravi B., Bhandari M., Gandhi R., et al. (2020). Cannabis use and sport: a systematic review. Sports Health 12 189–199. [PMC free article] [PubMed[]
  • Dodd G. T., Mancini G., Lutz B., Luckman S. M. (2010). The peptide hemopressin acts through CB1 cannabinoid receptors to reduce food intake in rats and mice. J. Neurosci. 30 7369–7376. 10.1523/JNEUROSCI.5455-09.2010 [PMC free article] [PubMed] [CrossRef[]
  • Dragano N. R., Haddad-Tovolli R., Velloso L. A. (2017). Leptin, neuroinflammation and obesity. Front. Horm. Res. 48 84–96. 10.1159/000452908 [PubMed] [CrossRef[]
  • Dyall S. C., Mandhair H. K., Fincham R. E. A., Kerr D. M., Roche M., Molina-Holgado F. (2016). Distinctive effects of eicosapentaenoic and docosahexaenoic acids in regulating neural stem cell fate are mediated via endocannabinoid signalling pathways. Neuropharmacology 107 387–395. 10.1016/j.neuropharm.2016.03.055 [PubMed] [CrossRef[]
  • Egertová M., Cravatt B. F., Elphick M. R. (2003). Comparative analysis of fatty acid amide hydrolase and cb(1) cannabinoid receptor expression in the mouse brain: evidence of a widespread role for fatty acid amide hydrolase in regulation of endocannabinoid signaling. Neuroscience 119 481–496. 10.1016/s0306-4522(03)00145-3 [PubMed] [CrossRef[]
  • El Swefy S., Hasan R. A., Ibrahim A., Mahmoud M. F. (2016). Curcumin and hemopressin treatment attenuates cholestasis-induced liver fibrosis in rats: role of CB1 receptors. Naunyn Schmiedebergs Arch. Pharmacol. 389 103–116. 10.1007/s00210-015-1181-7 [PubMed] [CrossRef[]
  • Esposito G., De Filippis D., Carnuccio R., Izzo A. A., Iuvone T. (2006). The marijuana component cannabidiol inhibits beta-amyloid-induced tau protein hyperphosphorylation through Wnt/beta-catenin pathway rescue in PC12 cells. J. Mol. Med. 84 253–258. 10.1007/s00109-005-0025-1 [PubMed] [CrossRef[]
  • Facci L., Dal Toso R., Romanello S., Buriani A., Skaper S. D., Leon A. (1995). Mast cells express a peripheral cannabinoid receptor with differential sensitivity to anandamide and palmitoylethanolamide. Proc. Natl. Acad. Sci. U.S.A. 92 3376–3380. 10.1073/pnas.92.8.3376 [PMC free article] [PubMed] [CrossRef[]
  • Fang R., Li X. (2015). A regular yoga intervention for staff nurse sleep quality and work stress: a randomised controlled trial. J. Clin. Nurs. 24 3374–3379. 10.1111/jocn.12983 [PubMed] [CrossRef[]
  • Fattore L., Spano M. S., Altea S., Angius F., Fadda P., Fratta W. (2007). Cannabinoid self-administration in rats: sex differences and the influence of ovarian function. Br. J. Pharmacol. 152 795–804. [PMC free article] [PubMed[]
  • Fernández-Suárez D., Celorrio M., Riezu-Boj J. I., Ugarte A., Pacheco R., González H., et al. (2014). Monoacylglycerol lipase inhibitor JZL184 is neuroprotective and alters glial cell phenotype in the chronic MPTP mouse model. Neurobiol. Aging 35 2603–2616. 10.1016/j.neurobiolaging.2014.05.021 [PubMed] [CrossRef[]
  • Ferrari D., Chiozzi P., Falzoni S., Dal Susino M., Collo G., Buell G., et al. (1997). ATP-mediated cytotoxicity in microglial cells. Neuropharmacology 36 1295–1301. [PubMed[]
  • Ferreira C. R., Van Karnebeek C. D. M., Vockley J., Blau N. (2019). A proposed nosology of inborn errors of metabolism. Genet. Med. 21 102–106. [PMC free article] [PubMed[]
  • Ferreira G. C., McKenna M. C. (2017). L-carnitine and acetyl-L-carnitine roles and neuroprotection in developing brain. Neurochem. Res. 42 1661–1675. [PMC free article] [PubMed[]
  • Field T., Diego M., Delgado J., Medina L. (2013). Tai chi/yoga reduces prenatal depression, anxiety and sleep disturbances. Complement. Ther. Clin. Pract. 19 6–10. 10.1016/j.ctcp.2012.10.001 [PMC free article] [PubMed] [CrossRef[]
  • Figueiredo P. R., Tolomeo S., Steele J. D., Baldacchino A. (2020). Neurocognitive consequences of chronic cannabis use: a systematic review and meta-analysis. Neurosci. Biobehav. Rev. 108 358–369. 10.1016/j.neubiorev.2019.10.014 [PubMed] [CrossRef[]
  • Filbey F. M., Aslan S., Calhoun V. D., Spence J. S., Damaraju E., Caprihan A., et al. (2014). Long-term effects of marijuana use on the brain. Proc. Natl. Acad. Sci. U.S.A. 111 16913–16918. [PMC free article] [PubMed[]
  • Fiskerstrand T., H’mida-Ben Brahim D., Johansson S., M’zahem A., Haukanes B. I., Drouot N., et al. (2010). Mutations in ABHD12 cause the neurodegenerative disease PHARC: an inborn error of endocannabinoid metabolism. Am. J. Hum. Genet. 87 410–417. 10.1016/j.ajhg.2010.08.002 [PMC free article] [PubMed] [CrossRef[]
  • Flanagan J. M., Gerber A. L., Cadet J. L., Beutler E., Sipe J. C. (2006). The fatty acid amide hydrolase 385 A/A (P129T) variant: haplotype analysis of an ancient missense mutation and validation of risk for drug addiction. Hum. Genet. 120 581–588. 10.1007/s00439-006-0250-x [PubMed] [CrossRef[]
  • Foltin R. W., Brady J. V., Fischman M. W. (1986). Behavioral analysis of marijuana effects on food intake in humans. Pharmacol. Biochem. Behav. 25 577–582. [PubMed[]
  • Ford C. G., Vowles K. E., Smith B. W., Kinney A. Y. (2020). Mindfulness and meditative movement interventions for men living with cancer: a meta-analysis. Ann. Behav. Med. 54 360–373. 10.1093/abm/kaz053 [PMC free article] [PubMed] [CrossRef[]
  • Formolo D. A., Gaspar J. M., Melo H. M., Eichwald T., Zepeda R. J., Latini A., et al. (2019). Deep brain stimulation for obesity: a review and future directions. Front. Neurosci. 13:323. 10.3389/fnins.2019.00323 [PMC free article] [PubMed] [CrossRef[]
  • Freitas H. R., Ferreira G. D. C., Trevenzoli I. H., Oliveira K. J., De Melo Reis R. A. (2017). Fatty acids, antioxidants and physical activity in brain aging. Nutrients 9:1263[]
  • Freitas H. R., Isaac A. R., Malcher-Lopes R., Diaz B. L., Trevenzoli I. H., De Melo Reis R. A. (2018). Polyunsaturated fatty acids and endocannabinoids in health and disease. Nutr. Neurosci. 21 695–714. [PubMed[]
  • Friedman J. M. (2019). Leptin and the endocrine control of energy balance. Nat. Metab. 1 754–764. [PubMed[]
  • Fuss J., Steinle J., Bindila L., Auer M. K., Kirchherr H., Lutz B., et al. (2015). A runner’s high depends on cannabinoid receptors in mice. Proc. Natl. Acad. Sci. U.S.A. 112 13105–13108. 10.1073/pnas.1514996112 [PMC free article] [PubMed] [CrossRef[]
  • Galles C., Prez G. M., Penkov S., Boland S., Porta E. O. J., Altabe S. G., et al. (2018). Endocannabinoids in Caenorhabditis elegans are essential for the mobilization of cholesterol from internal reserves. Sci. Rep. 8:6398. 10.1038/s41598-018-24925-8 [PMC free article] [PubMed] [CrossRef[]
  • Gandhi K., Li C., German N., Skobowiat C., Carrillo M., Kallem R. R., et al. (2018). Effect of maternal high-fat diet on key components of the placental and hepatic endocannabinoid system. Am. J. Physiol. Endocrinol. Metab. 314 E322–E333. 10.1152/ajpendo.00119.2017 [PMC free article] [PubMed] [CrossRef[]
  • García-Arencibia M., González S., De Lago E., Ramos J. A., Mechoulam R., Fernández-Ruiz J. (2007). Evaluation of the neuroprotective effect of cannabinoids in a rat model of Parkinson’s disease: importance of antioxidant and cannabinoid receptor-independent properties. Brain Res. 1134 162–170. 10.1016/j.brainres.2006.11.063 [PubMed] [CrossRef[]
  • Geisler B. P. (2016). Cardiovascular benefits of the Mediterranean diet are driven by stroke reduction and possibly by decreased atrial fibrillation incidence. Am. J. Med. 129:e11. 10.1016/j.amjmed.2015.04.046 [PubMed] [CrossRef[]
  • Gertsch J., Leonti M., Raduner S., Racz I., Chen J. Z., Xie X. Q., et al. (2008). Beta-caryophyllene is a dietary cannabinoid. Proc. Natl. Acad. Sci. U.S.A. 105 9099–9104. [PMC free article] [PubMed[]
  • Gertsch J., Pertwee R. G., Di Marzo V. (2010). Phytocannabinoids beyond the cannabis plant – do they exist? Br. J. Pharmacol. 160 523–529. 10.1111/j.1476-5381.2010.00745.x [PMC free article] [PubMed] [CrossRef[]
  • Ghaffari B. D., Kluger B. (2014). Mechanisms for alternative treatments in Parkinson’s disease: acupuncture, tai chi, and other treatments. Curr. Neurol. Neurosci. Rep. 14:451. 10.1007/s11910-014-0451-y [PubMed] [CrossRef[]
  • Gjerstad J. K., Lightman S. L., Spiga F. (2018). Role of glucocorticoid negative feedback in the regulation of HPA axis pulsatility. Stress 21 403–416. [PMC free article] [PubMed[]
  • Glass M., Dragunow M., Faull R. L. (2000). The pattern of neurodegeneration in Huntington’s disease: a comparative study of cannabinoid, dopamine, adenosine and GABA(A) receptor alterations in the human basal ganglia in Huntington’s disease. Neuroscience 97 505–519. [PubMed[]
  • Gluckman P. D., Hanson M. A., Low F. M. (2019). Evolutionary and developmental mismatches are consequences of adaptive developmental plasticity in humans and have implications for later disease risk. Philos. Trans. R Soc. Lond. B Biol. Sci. 374:20180109. 10.1098/rstb.2018.0109 [PMC free article] [PubMed] [CrossRef[]
  • Gomes I., Grushko J. S., Golebiewska U., Hoogendoorn S., Gupta A., Heimann A. S., et al. (2009). Novel endogenous peptide agonists of cannabinoid receptors. FASEB J. 23 3020–3029. [PMC free article] [PubMed[]
  • Gomes T. M., Dias Da Silva D., Carmo H., Carvalho F., Silva J. P. (2020). Epigenetics and the endocannabinoid system signaling: an intricate interplay modulating neurodevelopment. Pharmacol. Res. 162:105237. 10.1016/j.phrs.2020.105237 [PubMed] [CrossRef[]
  • Grimaldi P., Pucci M., Di Siena S., Di Giacomo D., Pirazzi V., Geremia R., et al. (2012). The faah gene is the first direct target of estrogen in the testis: role of histone demethylase LSD1. Cell. Mol. Life Sci. 69 4177–4190. 10.1007/s00018-012-1074-6 [PubMed] [CrossRef[]
  • Grzywacz A., Barczak W., Chmielowiec J., Chmielowiec K., Suchanecka A., Trybek G., et al. (2020). Contribution of dopamine transporter gene methylation status to cannabis dependency. Brain Sci. 10:400. 10.3390/brainsci10060400 [PMC free article] [PubMed] [CrossRef[]
  • Gubellini P., Picconi B., Bari M., Battista N., Calabresi P., Centonze D., et al. (2002). Experimental Parkinsonism alters endocannabinoid degradation: implications for striatal glutamatergic transmission. J. Neurosci. 22 6900–6907. 10.1523/JNEUROSCI.22-16-06900.2002 [PMC free article] [PubMed] [CrossRef[]
  • Habib A. M., Okorokov A. L., Hill M. N., Bras J. T., Lee M. C., Li S., et al. (2019). Microdeletion in a FAAH pseudogene identified in a patient with high anandamide concentrations and pain insensitivity. Br. J. Anaesth. 123 e249–e253. 10.1016/j.bja.2019.02.019 [PMC free article] [PubMed] [CrossRef[]
  • Haspula D., Clark M. A. (2020). Cannabinoid receptors: an update on cell signaling, pathophysiological roles and therapeutic opportunities in neurological, cardiovascular, and inflammatory diseases. Int. J. Mol. Sci. 21:7693. 10.3390/ijms21207693 [PMC free article] [PubMed] [CrossRef[]
  • Hebert-Chatelain E., Desprez T., Serrat R., Bellocchio L., Soria-Gomez E., Busquets-Garcia A., et al. (2016). A cannabinoid link between mitochondria and memory. Nature 539 555–559. [PubMed[]
  • Heimann A. S., Dale C. S., Guimarães F. S., Reis R. A. M., Navon A., Shmuelov M. A., et al. (2020a). Hemopressin as a breakthrough for the cannabinoid field. Neuropharmacology 183:108406. 10.1016/j.neuropharm.2020.108406 [PubMed] [CrossRef[]
  • Heimann A. S., Giardini A. C., Sant’anna M. B., Dos Santos N. B., Gewehr M. C. F., Munhoz C. D., et al. (2020b). NFKF is a synthetic fragment derived from rat hemopressin that protects mice from neurodegeneration. Neurosci. Lett. 721:134765. 10.1016/j.neulet.2020.134765 [PubMed] [CrossRef[]
  • Herkenham M., Lynn A. B., Johnson M. R., Melvin L. S., De Costa B. R., Rice K. C. (1991). Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. J. Neurosci. 11 563–583. 10.1523/JNEUROSCI.11-02-00563.1991 [PMC free article] [PubMed] [CrossRef[]
  • Herkenham M., Lynn A. B., Little M. D., Johnson M. R., Melvin L. S., De Costa B. R., et al. (1990). Cannabinoid receptor localization in brain. Proc. Natl. Acad. Sci. U.S.A. 87 1932–1936. [PMC free article] [PubMed[]
  • Herman J. P., Tasker J. G., Ziegler D. R., Cullinan W. E. (2002). Local circuit regulation of paraventricular nucleus stress integration: glutamate-GABA connections. Pharmacol. Biochem. Behav. 71 457–468. 10.1016/s0091-3057(01)00681-5 [PubMed] [CrossRef[]
  • Hernandez-Avila C. A., Rounsaville B. J., Kranzler H. R. (2004). Opioid-, cannabis- and alcohol-dependent women show more rapid progression to substance abuse treatment. Drug Alcohol Depend. 74 265–272. 10.1016/j.drugalcdep.2004.02.001 [PubMed] [CrossRef[]
  • Heyman E., Gamelin F. X., Goekint M., Piscitelli F., Roelands B., Leclair E., et al. (2012). Intense exercise increases circulating endocannabinoid and BDNF levels in humans–possible implications for reward and depression. Psychoneuroendocrinology 37 844–851. 10.1016/j.psyneuen.2011.09.017 [PubMed] [CrossRef[]
  • Hill M. N., Titterness A. K., Morrish A. C., Carrier E. J., Lee T. T., Gil-Mohapel J., et al. (2010). Endogenous cannabinoid signaling is required for voluntary exercise-induced enhancement of progenitor cell proliferation in the hippocampus. Hippocampus 20 513–523. 10.1002/hipo.20647 [PMC free article] [PubMed] [CrossRef[]
  • Holland J. (2010). The Pot Book: A Complete Guide to Cannabis. Rochester, VT: Inner Traditions/Bear. []
  • Horváth B., Mukhopadhyay P., Kechrid M., Patel V., Tanchian G., Wink D. A., et al. (2012). β-Caryophyllene ameliorates cisplatin-induced nephrotoxicity in a cannabinoid 2 receptor-dependent manner. Free Radic. Biol. Med. 52 1325–1333. 10.1016/j.freeradbiomed.2012.01.014 [PMC free article] [PubMed] [CrossRef[]
  • Hurley M. J., Mash D. C., Jenner P. (2003). Expression of cannabinoid CB1 receptor mRNA in basal ganglia of normal and parkinsonian human brain. J. Neural Transm. 110 1279–1288. 10.1007/s00702-003-0033-7 [PubMed] [CrossRef[]
  • Ibrahim M. M. (2010). Subcutaneous and visceral adipose tissue: structural and functional differences. Obes. Rev. 11 11–18. [PubMed[]
  • Irving A., Abdulrazzaq G., Chan S. L. F., Penman J., Harvey J., Alexander S. P. H. (2017). Cannabinoid receptor-related orphan G protein-coupled receptors. Adv. Pharmacol. 80 223–247. [PubMed[]
  • Isaac A. R., De Velasco P. C., Fraga K. Y. D., Tavares-Do-Carmo M. D. G., Campos R. M. P., Iannotti F. A., et al. (2021). Maternal omega-3 intake differentially affects the endocannabinoid system in the progeny’s neocortex and hippocampus: impact on synaptic markers: n-3 maternal diet sway progeny’s synaptic markers. J. Nutr. Biochem. 96:108782. 10.1016/j.jnutbio.2021.108782 [PubMed] [CrossRef[]
  • Jacobs T. L., Epel E. S., Lin J., Blackburn E. H., Wolkowitz O. M., Bridwell D. A., et al. (2011). Intensive meditation training, immune cell telomerase activity, and psychological mediators. Psychoneuroendocrinology 36 664–681. 10.1016/j.psyneuen.2010.09.010 [PubMed] [CrossRef[]
  • Jager G., Kahn R. S., Van Den Brink W., Van Ree J. M., Ramsey N. F. (2006). Long-term effects of frequent cannabis use on working memory and attention: an fMRI study. Psychopharmacology 185 358–368. 10.1007/s00213-005-0298-7 [PubMed] [CrossRef[]
  • Jannuzzi L. B., Pereira-Acacio A., Ferreira B. S. N., Silva-Pereira D., Veloso-Santos J. P. M., Alves-Bezerra D. S., et al. (2021). Undernutrition – thirty years of the regional basic diet: the legacy of Naíde Teodósio in different fields of knowledge. Nutr. Neurosci. 1–22. 10.1080/1028415X.2021.1915631 [PubMed] [CrossRef[]
  • Javed H., Azimullah S., Haque M. E., Ojha S. K. (2016). Cannabinoid type 2 (CB2) receptors activation protects against oxidative stress and neuroinflammation associated dopaminergic neurodegeneration in rotenone model of Parkinson’s disease. Front. Neurosci. 10:321. 10.3389/fnins.2016.00321 [PMC free article] [PubMed] [CrossRef[]
  • Jimenez-Blasco D., Busquets-Garcia A., Hebert-Chatelain E., Serrat R., Vicente-Gutierrez C., Ioannidou C., et al. (2020). Glucose metabolism links astroglial mitochondria to cannabinoid effects. Nature 583 603–608. 10.1038/s41586-020-2470-y [PubMed] [CrossRef[]
  • Jin K., Simpkins J. W., Ji X., Leis M., Stambler I. (2014). The critical need to promote research of aging and aging-related diseases to improve health and longevity of the elderly population. Aging Dis. 6 1–5. 10.14336/AD.2014.1210 [PMC free article] [PubMed] [CrossRef[]
  • Jindal V., Gupta S., Das R. (2013). Molecular mechanisms of meditation. Mol. Neurobiol. 48 808–811. [PubMed[]
  • Jones A. M., Carter H. (2000). The effect of endurance training on parameters of aerobic fitness. Sports Med. 29 373–386. [PubMed[]
  • Jones P. J., Lin L., Gillingham L. G., Yang H., Omar J. M. (2014). Modulation of plasma N-acylethanolamine levels and physiological parameters by dietary fatty acid composition in humans. J. Lipid Res. 55 2655–2664. 10.1194/jlr.P051235 [PMC free article] [PubMed] [CrossRef[]
  • Jonsson J., Renault K. M., Garcia-Calzon S., Perfilyev A., Estampador A. C., Norgaard K., et al. (2021). Lifestyle intervention in pregnant women with obesity impacts cord blood DNA methylation which associates with body composition in the offspring. Diabetes 70 854–866. 10.2337/db20-0487 [PMC free article] [PubMed] [CrossRef[]
  • Joss-Moore L. A., Lane R. H., Albertine K. H. (2015). Epigenetic contributions to the developmental origins of adult lung disease. Biochem Cell Biol 93 119–127. [PMC free article] [PubMed[]
  • Kano M., Ohno-Shosaku T., Hashimotodani Y., Uchigashima M., Watanabe M. (2009). Endocannabinoid-mediated control of synaptic transmission. Physiol Rev 89 309–380. [PubMed[]
  • Katona I., Freund T. F. (2008). Endocannabinoid signaling as a synaptic circuit breaker in neurological disease. Nat Med 14 923–930. [PubMed[]
  • Kaur R., Ambwani S. R., Singh S. (2016). Endocannabinoid system: a multi-facet therapeutic target. Curr. Clin. Pharmacol. 11 110–117. 10.2174/1574884711666160418105339 [PubMed] [CrossRef[]
  • Kelly T., Yang W., Chen C. S., Reynolds K., He J. (2008). Global burden of obesity in 2005 and projections to 2030. Int. J. Obes. 32 1431–1437. [PubMed[]
  • Khalsa D. S., Newberg A. B. (2021). Spiritual fitness: a new dimension in Alzheimer’s disease prevention. J. Alzheimers Dis. 80 505–519. 10.3233/JAD-201433 [PMC free article] [PubMed] [CrossRef[]
  • King-Himmelreich T. S., Schramm S., Wolters M. C., Schmetzer J., Moser C. V., Knothe C., et al. (2016). The impact of endurance exercise on global and AMPK gene-specific DNA methylation. Biochem. Biophys. Res. Commun. 474 284–290. 10.1016/j.bbrc.2016.04.078 [PubMed] [CrossRef[]
  • Kirkham T. C., Williams C. M. (2001). Endogenous cannabinoids and appetite. Nutr. Res. Rev. 14 65–86. [PubMed[]
  • Klauke A. L., Racz I., Pradier B., Markert A., Zimmer A. M., Gertsch J., et al. (2014). The cannabinoid CB2 receptor-selective phytocannabinoid beta-caryophyllene exerts analgesic effects in mouse models of inflammatory and neuropathic pain. Eur. Neuropsychopharmacol. 24 608–620. [PubMed[]
  • Koch M., Varela L., Kim J. G., Kim J. D., Hernández-Nuño F., Simonds S. E., et al. (2015). Hypothalamic POMC neurons promote cannabinoid-induced feeding. Nature 519 45–50. 10.1038/nature14260 [PMC free article] [PubMed] [CrossRef[]
  • Koppel J., Vingtdeux V., Marambaud P., D’abramo C., Jimenez H., Stauber M., et al. (2014). CB2 receptor deficiency increases amyloid pathology and alters tau processing in a transgenic mouse model of Alzheimer’s disease. Mol. Med. 20 29–36. [PMC free article] [PubMed[]
  • Korte G., Dreiseitel A., Schreier P., Oehme A., Locher S., Geiger S., et al. (2010). Tea catechins’ affinity for human cannabinoid receptors. Phytomedicine 17 19–22. 10.1016/j.phymed.2009.10.001 [PubMed] [CrossRef[]
  • Kucerova J., Tabiova K., Drago F., Micale V. (2014). Therapeutic potential of cannabinoids in schizophrenia. Recent Pat. CNS Drug Discov. 9 13–25. [PubMed[]
  • Kwok J. Y. Y., Kwan J. C. Y., Auyeung M., Mok V. C. T., Lau C. K. Y., Choi K. C., et al. (2019). Effects of mindfulness yoga vs stretching and resistance training exercises on anxiety and depression for people with Parkinson disease: a randomized clinical trial. JAMA Neurol. 76 755–763. 10.1001/jamaneurol.2019.0534 [PMC free article] [PubMed] [CrossRef[]
  • Labbé K., Murley A., Nunnari J. (2014). Determinants and functions of mitochondrial behavior. Annu. Rev. Cell Dev. Biol. 30 357–391. [PubMed[]
  • Labra V. C., Santibáñez C. A., Gajardo-Gómez R., Díaz E. F., Gómez G. I., Orellana J. A. (2018). The neuroglial dialog between cannabinoids and hemichannels. Front. Mol. Neurosci. 11:79. 10.3389/fnmol.2018.00079 [PMC free article] [PubMed] [CrossRef[]
  • Lafourcade M., Larrieu T., Mato S., Duffaud A., Sepers M., Matias I., et al. (2011). Nutritional omega-3 deficiency abolishes endocannabinoid-mediated neuronal functions. Nat. Neurosci. 14 345–350. 10.1038/nn.2736 [PubMed] [CrossRef[]
  • LaFrance E. M., Glodosky N. C., Bonn-Miller M., Cuttler C. (2020). Short and long-term effects of cannabis on symptoms of post-traumatic stress disorder. J. Affect. Disord. 274 298–304. 10.1016/j.jad.2020.05.132 [PubMed] [CrossRef[]
  • Lahesmaa M., Eriksson O., Gnad T., Oikonen V., Bucci M., Hirvonen J., et al. (2018). Cannabinoid type 1 receptors are upregulated during acute activation of brown adipose tissue. Diabetes 67 1226–1236. [PubMed[]
  • Larasati Y. A., Yoneda-Kato N., Nakamae I., Yokoyama T., Meiyanto E., Kato J. Y. (2018). Curcumin targets multiple enzymes involved in the ROS metabolic pathway to suppress tumor cell growth. Sci. Rep. 8:2039. 10.1038/s41598-018-20179-6 [PMC free article] [PubMed] [CrossRef[]
  • Larrieu T., Madore C., Joffre C., Layé S. (2012). Nutritional n-3 polyunsaturated fatty acids deficiency alters cannabinoid receptor signaling pathway in the brain and associated anxiety-like behavior in mice. J. Physiol. Biochem. 68 671–681. 10.1007/s13105-012-0179-6 [PubMed] [CrossRef[]
  • Lastres-Becker I., Molina-Holgado F., Ramos J. A., Mechoulam R., Fernández-Ruiz J. (2005). Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: relevance to Parkinson’s disease. Neurobiol. Dis. 19 96–107. 10.1016/j.nbd.2004.11.009 [PubMed] [CrossRef[]
  • Laurikainen H., Tuominen L., Tikka M., Merisaari H., Armio R. L., Sormunen E., et al. (2019). Sex difference in brain CB1 receptor availability in man. Neuroimage 184 834–842. [PubMed[]
  • Lee J. H., Agacinski G., Williams J. H., Wilcock G. K., Esiri M. M., Francis P. T., et al. (2010). Intact cannabinoid CB1 receptors in the Alzheimer’s disease cortex. Neurochem. Int. 57 985–989. 10.1016/j.neuint.2010.10.010 [PubMed] [CrossRef[]
  • Lee J., Wolfgang M. J. (2012). Metabolomic profiling reveals a role for CPT1c in neuronal oxidative metabolism. BMC Biochem. 13:23. 10.1186/1471-2091-13-23 [PMC free article] [PubMed] [CrossRef[]
  • Lee K. S., Asgar J., Zhang Y., Chung M. K., Ro J. Y. (2013). The role of androgen receptor in transcriptional modulation of cannabinoid receptor type 1 gene in rat trigeminal ganglia. Neuroscience 254 395–403. 10.1016/j.neuroscience.2013.09.014 [PMC free article] [PubMed] [CrossRef[]
  • Li M. D., Vera N. B., Yang Y., Zhang B., Ni W., Ziso-Qejvanaj E., et al. (2018). Adipocyte OGT governs diet-induced hyperphagia and obesity. Nat. Commun. 9:5103. 10.1038/s41467-018-07461-x [PMC free article] [PubMed] [CrossRef[]
  • Ligresti A., De Petrocellis L., Di Marzo V. (2016). From phytocannabinoids to cannabinoid receptors and endocannabinoids: pleiotropic physiological and pathological roles through complex pharmacology. Physiol. Rev. 96 1593–1659. 10.1152/physrev.00002.2016 [PubMed] [CrossRef[]
  • Lillycrop K. A., Burdge G. C. (2015). Maternal diet as a modifier of offspring epigenetics. J. Dev. Orig. Health Dis. 6 88–95. [PubMed[]
  • Lim H. K., Lee H. R., Do S. H. (2015). Stimulation of cannabinoid receptors by using Rubus coreanus extracts to control osteoporosis in aged male rats. Aging Male 18 124–132. 10.3109/13685538.2014.949661 [PubMed] [CrossRef[]
  • Liu M. W., Su M. X., Wang Y. H., Wei W., Qin L. F., Liu X., et al. (2014). Effect of melilotus extract on lung injury by upregulating the expression of cannabinoid CB2 receptors in septic rats. BMC Complement. Altern. Med. 14:94. 10.1186/1472-6882-14-94 [PMC free article] [PubMed] [CrossRef[]
  • Llorente-Berzal A., Terzian A. L., Di Marzo V., Micale V., Viveros M. P., Wotjak C. T. (2015). 2-AG promotes the expression of conditioned fear via cannabinoid receptor type 1 on GABAergic neurons. Psychopharmacology 232 2811–2825. 10.1007/s00213-015-3917-y [PubMed] [CrossRef[]
  • Lomazzo E., Konig F., Abassi L., Jelinek R., Lutz B. (2017). Chronic stress leads to epigenetic dysregulation in the neuropeptide-Y and cannabinoid CB1 receptor genes in the mouse cingulate cortex. Neuropharmacology 113 301–313. 10.1016/j.neuropharm.2016.10.008 [PubMed] [CrossRef[]
  • Lopez-Gallardo M., Lopez-Rodriguez A. B., Llorente-Berzal A., Rotllant D., Mackie K., Armario A., et al. (2012). Maternal deprivation and adolescent cannabinoid exposure impact hippocampal astrocytes, CB1 receptors and brain-derived neurotrophic factor in a sexually dimorphic fashion. Neuroscience 204 90–103. 10.1016/j.neuroscience.2011.09.063 [PMC free article] [PubMed] [CrossRef[]
  • Lotan I., Treves T. A., Roditi Y., Djaldetti R. (2014). Cannabis (medical marijuana) treatment for motor and non-motor symptoms of Parkinson disease: an open-label observational study. Clin. Neuropharmacol. 37 41–44. 10.1097/WNF.0000000000000016 [PubMed] [CrossRef[]
  • Ma H., Zhang G., Mou C., Fu X., Chen Y. (2018). Peripheral CB1 receptor neutral antagonist, AM6545, ameliorates hypometabolic obesity and improves adipokine secretion in monosodium glutamate induced obese mice. Front. Pharmacol. 9:156. 10.3389/fphar.2018.00156 [PMC free article] [PubMed] [CrossRef[]
  • Maccarrone M., Bab I., Biro T., Cabral G. A., Dey S. K., Di Marzo V., et al. (2015). Endocannabinoid signaling at the periphery: 50 years after THC. Trends Pharmacol. Sci. 36 277–296. 10.1016/j.tips.2015.02.008 [PMC free article] [PubMed] [CrossRef[]
  • Maia J., Almada M., Silva A., Correia-Da-Silva G., Teixeira N., Sa S. I., et al. (2017). The endocannabinoid system expression in the female reproductive tract is modulated by estrogen. J. Steroid Biochem. Mol. Biol. 174 40–47. [PubMed[]
  • Maia J., Midao L., Cunha S. C., Almada M., Fonseca B. M., Braga J., et al. (2019). Effects of cannabis tetrahydrocannabinol on endocannabinoid homeostasis in human placenta. Arch. Toxicol. 93 649–658. [PubMed[]
  • Mallipeddi S., Janero D. R., Zvonok N., Makriyannis A. (2017). Functional selectivity at G-protein coupled receptors: advancing cannabinoid receptors as drug targets. Biochem. Pharmacol. 128 1–11. 10.1016/j.bcp.2016.11.014 [PMC free article] [PubMed] [CrossRef[]
  • Mancino S., Burokas A., Gutierrez-Cuesta J., Gutierrez-Martos M., Martin-Garcia E., Pucci M., et al. (2015). Epigenetic and proteomic expression changes promoted by eating addictive-like behavior. Neuropsychopharmacology 40 2788–2800. 10.1038/npp.2015.129 [PMC free article] [PubMed] [CrossRef[]
  • Manuel I., González De San Román E., Giralt M. T., Ferrer I., Rodríguez-Puertas R. (2014). Type-1 cannabinoid receptor activity during Alzheimer’s disease progression. J. Alzheimers Dis. 42 761–766. [PubMed[]
  • Marco E. M., Echeverry-Alzate V., Lopez-Moreno J. A., Gine E., Penasco S., Viveros M. P. (2014). Consequences of early life stress on the expression of endocannabinoid-related genes in the rat brain. Behav. Pharmacol. 25 547–556. 10.1097/FBP.0000000000000068 [PubMed] [CrossRef[]
  • Marsicano G., Lutz B. (1999). Expression of the cannabinoid receptor CB1 in distinct neuronal subpopulations in the adult mouse forebrain. Eur. J. Neurosci. 11 4213–4225. [PubMed[]
  • Mazier W., Saucisse N., Gatta-Cherifi B., Cota D. (2015). The endocannabinoid system: pivotal orchestrator of obesity and metabolic disease. Trends Endocrinol. Metab. 26 524–537. 10.1016/j.tem.2015.07.007 [PubMed] [CrossRef[]
  • Mazzola C., Micale V., Drago F. (2003). Amnesia induced by beta-amyloid fragments is counteracted by cannabinoid CB1 receptor blockade. Eur. J. Pharmacol. 477 219–225. 10.1016/j.ejphar.2003.08.026 [PubMed] [CrossRef[]
  • McDougle D. R., Watson J. E., Abdeen A. A., Adili R., Caputo M. P., Krapf J. E., et al. (2017). Anti-inflammatory ω-3 endocannabinoid epoxides. Proc. Natl. Acad. Sci. U.S.A. 114 E6034–E6043. [PMC free article] [PubMed[]
  • McGavin J. J., Cochkanoff N. L., Poole E. I., Crosby K. M. (2019). 2-arachidonylglycerol interacts with nitric oxide in the dorsomedial hypothalamus to increase food intake and body weight in young male rats. Neurosci. Lett. 698 27–32. 10.1016/j.neulet.2019.01.008 [PubMed] [CrossRef[]
  • McKenna M. C., Scafidi S., Robertson C. L. (2015). Metabolic alterations in developing brain after injury: knowns and unknowns. Neurochem. Res. 40 2527–2543. [PMC free article] [PubMed[]
  • McKenna M. C., Schuck P. F., Ferreira G. C. (2019). Fundamentals of CNS energy metabolism and alterations in lysosomal storage diseases. J. Neurochem. 148 590–599. 10.1111/jnc.14577 [PubMed] [CrossRef[]
  • Meccariello R., Santoro A., D’angelo S., Morrone R., Fasano S., Viggiano A., et al. (2020). The epigenetics of the endocannabinoid system. Int. J. Mol. Sci. 21:1113[PMC free article] [PubMed[]
  • Mechoulam R., Gaoni Y. (1965). Hashish. IV. The isolation and structure of cannabinolic cannabidiolic and cannabigerolic acids. Tetrahedron 21 1223–1229. 10.1016/0040-4020(65)80064-3 [PubMed] [CrossRef[]
  • Mechoulam R., Parker L. A. (2013). The endocannabinoid system and the brain. Annu. Rev. Psychol. 64 21–47. [PubMed[]
  • Meslier V., Laiola M., Roager H. M., De Filippis F., Roume H., Quinquis B., et al. (2020). Mediterranean diet intervention in overweight and obese subjects lowers plasma cholesterol and causes changes in the gut microbiome and metabolome independently of energy intake. Gut 69 1258–1268. 10.1136/gutjnl-2019-320438 [PMC free article] [PubMed] [CrossRef[]
  • Metzler M. (2011). Disturbances in endocannabinoid metabolism causes autosomal recessive neurodegeneration. Clin. Genet. 79 221–222. 10.1111/j.1399-0004.2010.01611.x [PubMed] [CrossRef[]
  • Micale V., Drago F. (2018). Endocannabinoid system, stress and HPA axis. Eur. J. Pharmacol. 834 230–239. [PubMed[]
  • Micale V., Di Marzo V., Sulcova A., Wotjak C. T., Drago F. (2013). Endocannabinoid system and mood disorders: priming a target for new therapies. Pharmacol. Ther. 138 18–37. 10.1016/j.pharmthera.2012.12.002 [PubMed] [CrossRef[]
  • Micale V., Drago F., Noerregaard P. K., Elling C. E., Wotjak C. T. (2019). The cannabinoid CB1 antagonist TM38837 with limited penetrance to the brain shows reduced fear-promoting effects in mice. Front. Pharmacol. 10:207. 10.3389/fphar.2019.00207 [PMC free article] [PubMed] [CrossRef[]
  • Micale V., Mazzola C., Drago F. (2007). Endocannabinoids and neurodegenerative diseases. Pharmacol. Res. 56 382–392. [PubMed[]
  • Micale V., Stepan J., Jurik A., Pamplona F. A., Marsch R., Drago F., et al. (2017). Extinction of avoidance behavior by safety learning depends on endocannabinoid signaling in the hippocampus. J. Psychiatr. Res. 90 46–59. 10.1016/j.jpsychires.2017.02.002 [PubMed] [CrossRef[]
  • Micale V., Tabiova K., Kucerova J., Drago F. (2015). “Role of the endocannabinoid system in depression: from preclinical to clinical evidence,” in Cannabinoid Modulation of Emotion, Memory, and Motivation, eds Campolongo P., Fattore L. (New York, NY: Springer New York; ), 97–129. []
  • Min Y., Ma X., Sankaran K., Ru Y., Chen L., Baiocchi M., et al. (2019). Sex-specific association between gut microbiome and fat distribution. Nat. Commun. 10:2408[PMC free article] [PubMed[]
  • Miranda R. A., De Almeida M. M., Rocha C., De Brito Fassarella L., De Souza L. L., Souza A. F. P., et al. (2018). Maternal high-fat diet consumption induces sex-dependent alterations of the endocannabinoid system and redox homeostasis in liver of adult rat offspring. Sci. Rep. 8:14751. 10.1038/s41598-018-32906-0 [PMC free article] [PubMed] [CrossRef[]
  • Morena M., Patel S., Bains J. S., Hill M. N. (2016). Neurobiological interactions between stress and the endocannabinoid system. Neuropsychopharmacology 41 80–102. [PMC free article] [PubMed[]
  • Mulder J., Zilberter M., Pasquaré S. J., Alpár A., Schulte G., Ferreira S. G., et al. (2011). Molecular reorganization of endocannabinoid signalling in Alzheimer’s disease. Brain 134 1041–1060. 10.1093/brain/awr046 [PMC free article] [PubMed] [CrossRef[]
  • Muller C., Morales P., Reggio P. H. (2018). Cannabinoid ligands targeting TRP channels. Front. Mol. Neurosci. 11:487. 10.3389/fnmol.2018.00487 [PMC free article] [PubMed] [CrossRef[]
  • Muniyappa R., Sable S., Ouwerkerk R., Mari A., Gharib A. M., Walter M., et al. (2013). Metabolic effects of chronic cannabis smoking. Diabetes Care 36 2415–2422. [PMC free article] [PubMed[]
  • Murphy S. K., Itchon-Ramos N., Visco Z., Huang Z., Grenier C., Schrott R., et al. (2018). Cannabinoid exposure and altered DNA methylation in rat and human sperm. Epigenetics 13 1208–1221. [PMC free article] [PubMed[]
  • Muzik O., Diwadkar V. A. (2019). Hierarchical control systems for the regulation of physiological homeostasis and affect: can their interactions modulate mood and anhedonia? Neurosci. Biobehav. Rev. 105 251–261. 10.1016/j.neubiorev.2019.08.015 [PubMed] [CrossRef[]
  • Nashed M. G., Hardy D. B., Laviolette S. R. (2020). Prenatal cannabinoid exposure: emerging evidence of physiological and neuropsychiatric abnormalities. Front. Psychiatry 11:624275. 10.3389/fpsyt.2020.624275 [PMC free article] [PubMed] [CrossRef[]
  • Natale B. V., Gustin K. N., Lee K., Holloway A. C., Laviolette S. R., Natale D. R. C., et al. (2020). Delta9-tetrahydrocannabinol exposure during rat pregnancy leads to symmetrical fetal growth restriction and labyrinth-specific vascular defects in the placenta. Sci. Rep. 10:544. 10.1038/s41598-019-57318-6 [PMC free article] [PubMed] [CrossRef[]
  • Niquet J., Seo D. W., Wasterlain C. G. (2006). Mitochondrial pathways of neuronal necrosis. Biochem. Soc. Trans. 34 1347–1351. [PubMed[]
  • Nishiguchi K. M., Avila-Fernandez A., Van Huet R. A., Corton M., Pérez-Carro R., Martín-Garrido E., et al. (2014). Exome sequencing extends the phenotypic spectrum for ABHD12 mutations: from syndromic to nonsyndromic retinal degeneration. Ophthalmology 121 1620–1627. 10.1016/j.ophtha.2014.02.008 [PubMed] [CrossRef[]
  • Notarnicola M., Tutino V., Tafaro A., Bianco G., Guglielmi E., Caruso M. G. (2016). Dietary olive oil induces cannabinoid CB2 receptor expression in adipose tissue of Apc(Min/+) transgenic mice. Nutr. Healthy Aging 4 73–80. 10.3233/NHA-160008 [PMC free article] [PubMed] [CrossRef[]
  • O’Callaghan R. M., Ohle R., Kelly ÁM. (2007). The effects of forced exercise on hippocampal plasticity in the rat: a comparison of LTP, spatial- and non-spatial learning. Behav. Brain Res. 176 362–366. 10.1016/j.bbr.2006.10.018 [PubMed] [CrossRef[]
  • Oddi S., Caporali P., Dragotto J., Totaro A., Maiolati M., Scipioni L., et al. (2019). The endocannabinoid system is affected by cholesterol dyshomeostasis: insights from a murine model of Niemann Pick type C disease. Neurobiol. Dis. 130:104531. 10.1016/j.nbd.2019.104531 [PubMed] [CrossRef[]
  • Oliveira C. D. C., Castor M., Castor C., Costa ÁF., Ferreira R. C. M., Silva J. F. D., et al. (2019). Evidence for the involvement of opioid and cannabinoid systems in the peripheral antinociception mediated by resveratrol. Toxicol. Appl. Pharmacol. 369 30–38. 10.1016/j.taap.2019.02.004 [PubMed] [CrossRef[]
  • Oliver E. E., Hughes E. K., Puckett M. K., Chen R., Lowther W. T., Howlett A. C. (2020). Cannabinoid receptor interacting protein 1a (CRIP1a) in health and disease. Biomolecules 10:1609. 10.3390/biom10121609 [PMC free article] [PubMed] [CrossRef[]
  • Otrubova K., Ezzili C., Boger D. L. (2011). The discovery and development of inhibitors of fatty acid amide hydrolase (FAAH). Bioorg. Med. Chem. Lett. 21 4674–4685. [PMC free article] [PubMed[]
  • Pacher P., Bátkai S., Kunos G. (2006). The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol. Rev. 58 389–462. [PMC free article] [PubMed[]
  • Pagotto U., Marsicano G., Cota D., Lutz B., Pasquali R. (2006). The emerging role of the endocannabinoid system in endocrine regulation and energy balance. Endocr. Rev. 27 73–100. [PubMed[]
  • Palu A. K., Kim A. H., West B. J., Deng S., Jensen J., White L. (2008). The effects of Morinda citrifolia L. (noni) on the immune system: its molecular mechanisms of action. J. Ethnopharmacol. 115 502–506. 10.1016/j.jep.2007.10.023 [PubMed] [CrossRef[]
  • Pan J. P., Zhang H. Q., Wei W., Guo Y. F., Na X., Cao X. H., et al. (2011). Some subtypes of endocannabinoid/endovanilloid receptors mediate docosahexaenoic acid-induced enhanced spatial memory in rats. Brain Res. 1412 18–27. 10.1016/j.brainres.2011.07.015 [PubMed] [CrossRef[]
  • Park H. J., Bailey L. B., Shade D. C., Hausman D. B., Hohos N. M., Meagher R. B., et al. (2017). Distinctions in gene-specific changes in DNA methylation in response to folic acid supplementation between women with normal weight and obesity. Obes. Res. Clin. Pract. 11 665–676. 10.1016/j.orcp.2017.06.004 [PubMed] [CrossRef[]
  • Pertwee R. G. (2010). Receptors and channels targeted by synthetic cannabinoid receptor agonists and antagonists. Curr. Med. Chem. 17 1360–1381. 10.2174/092986710790980050 [PMC free article] [PubMed] [CrossRef[]
  • Petrosino S., Di Marzo V. (2010). FAAH and MAGL inhibitors: therapeutic opportunities from regulating endocannabinoid levels. Curr. Opin. Investig. Drugs 11 51–62. [PubMed[]
  • Petrovich G. D., Holland P. C., Gallagher M. (2005). Amygdalar and prefrontal pathways to the lateral hypothalamus are activated by a learned cue that stimulates eating. J. Neurosci. 25 8295–8302. 10.1523/JNEUROSCI.2480-05.2005 [PMC free article] [PubMed] [CrossRef[]
  • Pihlaja R., Takkinen J., Eskola O., Vasara J., López-Picón F. R., Haaparanta-Solin M., et al. (2015). Monoacylglycerol lipase inhibitor JZL184 reduces neuroinflammatory response in APdE9 mice and in adult mouse glial cells. J. Neuroinflammation 12:81. 10.1186/s12974-015-0305-9 [PMC free article] [PubMed] [CrossRef[]
  • Pisani A., Centonze D., Bernardi G., Calabresi P. (2005). Striatal synaptic plasticity: implications for motor learning and Parkinson’s disease. Mov. Disord. 20 395–402. [PubMed[]
  • Pistis M., O’Sullivan S. E. (2017). The role of nuclear hormone receptors in cannabinoid function. Adv. Pharmacol. 80 291–328. [PubMed[]
  • Pozo M., Claret M. (2018). Hypothalamic control of systemic glucose homeostasis: the pancreas connection. Trends Endocrinol. Metab. 29 581–594. 10.1016/j.tem.2018.05.001 [PubMed] [CrossRef[]
  • Price D. A., Martinez A. A., Seillier A., Koek W., Acosta Y., Fernandez E., et al. (2009). WIN55,212-2, a cannabinoid receptor agonist, protects against nigrostriatal cell loss in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson’s disease. Eur. J. Neurosci. 29 2177–2186. [PMC free article] [PubMed[]
  • Price N., Van Der Leij F., Jackson V., Corstorphine C., Thomson R., Sorensen A., et al. (2002). A novel brain-expressed protein related to carnitine palmitoyltransferase I. Genomics 80 433–442. 10.1006/geno.2002.6845 [PubMed] [CrossRef[]
  • Priestley R., Glass M., Kendall D. (2017). Functional selectivity at cannabinoid receptors. Adv. Pharmacol. 80 207–221. [PubMed[]
  • Prini P., Zamberletti E., Manenti C., Gabaglio M., Parolaro D., Rubino T. (2020). Neurobiological mechanisms underlying cannabis-induced memory impairment. Eur. Neuropsychopharmacol. 36 181–190. 10.1016/j.euroneuro.2020.02.002 [PubMed] [CrossRef[]
  • Proto M. C., Gazzerro P., Di Croce L., Santoro A., Malfitano A. M., Pisanti S., et al. (2012). Interaction of endocannabinoid system and steroid hormones in the control of colon cancer cell growth. J. Cell. Physiol. 227 250–258. 10.1002/jcp.22727 [PubMed] [CrossRef[]
  • Quarta C., Cota D. (2020). Anti-obesity therapy with peripheral CB1 blockers: from promise to safe(?) practice. Int. J. Obes. 44 2179–2193. 10.1038/s41366-020-0577-8 [PubMed] [CrossRef[]
  • Quezada S. M., Cross R. K. (2019). Cannabis and turmeric as complementary treatments for IBD and other digestive diseases. Curr. Gastroenterol. Rep. 21:2. 10.1007/s11894-019-0670-0 [PubMed] [CrossRef[]
  • Radd-Vagenas S., Duffy S. L., Naismith S. L., Brew B. J., Flood V. M., Fiatarone Singh M. A. (2018). Effect of the Mediterranean diet on cognition and brain morphology and function: a systematic review of randomized controlled trials. Am. J. Clin. Nutr. 107 389–404. 10.1093/ajcn/nqx070 [PubMed] [CrossRef[]
  • Ramer R., Schwarz R., Hinz B. (2019). Modulation of the endocannabinoid system as a potential anticancer strategy. Front. Pharmacol. 10:430. 10.3389/fphar.2019.00430 [PMC free article] [PubMed] [CrossRef[]
  • Ramírez B. G., Blázquez C., Gómez Del Pulgar T., Guzmán M., De Ceballos M. L. (2005). Prevention of Alzheimer’s disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation. J. Neurosci. 25 1904–1913. 10.1523/JNEUROSCI.4540-04.2005 [PMC free article] [PubMed] [CrossRef[]
  • Ramirez-Lopez M. T., Arco R., Decara J., Vazquez M., Noemi Blanco R., Alen F., et al. (2016a). Exposure to a highly caloric palatable diet during the perinatal period affects the expression of the endogenous cannabinoid system in the brain, liver and adipose tissue of adult rat offspring. PLoS One 11:e0165432. 10.1371/journal.pone.0165432 [PMC free article] [PubMed] [CrossRef[]
  • Ramirez-Lopez M. T., Arco R., Decara J., Vazquez M., Rivera P., Blanco R. N., et al. (2016b). Long-term effects of prenatal exposure to undernutrition on cannabinoid receptor-related behaviors: sex and tissue-specific alterations in the mRNA expression of cannabinoid receptors and lipid metabolic regulators. Front. Behav. Neurosci. 10:241. 10.3389/fnbeh.2016.00241 [PMC free article] [PubMed] [CrossRef[]
  • Ramirez-Lopez M. T., Vazquez M., Bindila L., Lomazzo E., Hofmann C., Blanco R. N., et al. (2015). Exposure to a highly caloric palatable diet during pregestational and gestational periods affects hypothalamic and hippocampal endocannabinoid levels at birth and induces adiposity and anxiety-like behaviors in male rat offspring. Front. Behav. Neurosci. 9:339. 10.3389/fnbeh.2015.00339 [PMC free article] [PubMed] [CrossRef[]
  • Rauschert S., Melton P. E., Burdge G., Craig J. M., Godfrey K. M., Holbrook J. D., et al. (2019). Maternal smoking during pregnancy induces persistent epigenetic changes into adolescence, independent of postnatal smoke exposure and is associated with cardiometabolic risk. Front. Genet. 10:770. 10.3389/fgene.2019.00770 [PMC free article] [PubMed] [CrossRef[]
  • Regehr W. G., Carey M. R., Best A. R. (2009). Activity-dependent regulation of synapses by retrograde messengers. Neuron 63 154–170. [PMC free article] [PubMed[]
  • Ren M., Tang Z., Wu X., Spengler R., Jiang H., Yang Y., et al. (2019). The origins of cannabis smoking: chemical residue evidence from the first millennium BCE in the Pamirs. Sci. Adv. 5:eaaw1391. 10.1126/sciadv.aaw1391 [PMC free article] [PubMed] [CrossRef[]
  • Richardson K. A., Hester A. K., Mclemore G. L. (2016). Prenatal cannabis exposure – the “first hit” to the endocannabinoid system. Neurotoxicol. Teratol. 58 5–14. [PubMed[]
  • Ritter S. L., Hall R. A. (2009). Fine-tuning of GPCR activity by receptor-interacting proteins. Nat. Rev. Mol. Cell Biol. 10 819–830. [PMC free article] [PubMed[]
  • Rivera P., Guerra-Cantera S., Vargas A., Diaz F., Garcia-Ubeda R., Tovar R., et al. (2020). Maternal hypercaloric diet affects factors involved in lipid metabolism and the endogenous cannabinoid systems in the hypothalamus of adult offspring: sex-specific response of astrocytes to palmitic acid and anandamide. Nutr. Neurosci. 1–14. 10.1080/1028415X.2020.1821519 [PubMed] [CrossRef[]
  • Rodrigues R. J., Tome A. R., Cunha R. A. (2015). ATP as a multi-target danger signal in the brain. Front. Neurosci. 9:148. 10.3389/fnins.2015.00148 [PMC free article] [PubMed] [CrossRef[]
  • Rogers J. P., Chesney E., Oliver D., Pollak T. A., Mcguire P., Fusar-Poli P., et al. (2020). Psychiatric and neuropsychiatric presentations associated with severe coronavirus infections: a systematic review and meta-analysis with comparison to the COVID-19 pandemic. Lancet Psychiatry 7 611–627. 10.1016/S2215-0366(20)30203-0 [PMC free article] [PubMed] [CrossRef[]
  • Roh E., Song D. K., Kim M. S. (2016). Emerging role of the brain in the homeostatic regulation of energy and glucose metabolism. Exp. Mol. Med. 48:e216[PMC free article] [PubMed[]
  • Rohde K., Keller M., La Cour Poulsen L., Bluher M., Kovacs P., Bottcher Y. (2019). Genetics and epigenetics in obesity. Metabolism 92 37–50. [PubMed[]
  • Romano-Lopez A., Mendez-Diaz M., Garcia F. G., Regalado-Santiago C., Ruiz-Contreras A. E., Prospero-Garcia O. (2016). Maternal separation and early stress cause long-lasting effects on dopaminergic and endocannabinergic systems and alters dendritic morphology in the nucleus accumbens and frontal cortex in rats. Dev. Neurobiol. 76 819–831. 10.1002/dneu.22361 [PubMed] [CrossRef[]
  • Rossi F., Bellini G., Luongo L., Manzo I., Tolone S., Tortora C., et al. (2016). Cannabinoid receptor 2 as antiobesity target: inflammation, fat storage, and browning modulation. J. Clin. Endocrinol. Metab. 101 3469–3478. 10.1210/jc.2015-4381 [PubMed] [CrossRef[]
  • Rossmeisl M., Jilkova Z. M., Kuda O., Jelenik T., Medrikova D., Stankova B., et al. (2012). Metabolic effects of n-3 PUFA as phospholipids are superior to triglycerides in mice fed a high-fat diet: possible role of endocannabinoids. PLoS One 7:e38834. 10.1371/journal.pone.0038834 [PMC free article] [PubMed] [CrossRef[]
  • Rotter A., Bayerlein K., Hansbauer M., Weiland J., Sperling W., Kornhuber J., et al. (2013). CB1 and CB2 receptor expression and promoter methylation in patients with cannabis dependence. Eur. Addict. Res. 19 13–20. 10.1159/000338642 [PubMed] [CrossRef[]
  • Rozenfeld R. (2011). Type I cannabinoid receptor trafficking: all roads lead to lysosome. Traffic 12 12–18. 10.1111/j.1600-0854.2010.01130.x [PubMed] [CrossRef[]
  • Rozenfeld R., Devi L. A. (2008). Regulation of CB1 cannabinoid receptor trafficking by the adaptor protein AP-3. FASEB J. 22 2311–2322. [PMC free article] [PubMed[]
  • Ruhl T., Karthaus N., Kim B. S., Beier J. P. (2020). The endocannabinoid receptors CB1 and CB2 affect the regenerative potential of adipose tissue MSCs. Exp. Cell Res. 389:111881. 10.1016/j.yexcr.2020.111881 [PubMed] [CrossRef[]
  • Russo E. B., Guy G. W., Robson P. J. (2007). Cannabis, pain, and sleep: lessons from therapeutic clinical trials of Sativex, a cannabis-based medicine. Chem. Biodivers. 4 1729–1743. 10.1002/cbdv.200790150 [PubMed] [CrossRef[]
  • Sadhasivam S., Alankar S., Maturi R., Vishnubhotla R. V., Mudigonda M., Pawale D., et al. (2020). Inner engineering practices and advanced 4-day isha yoga retreat are associated with cannabimimetic effects with increased endocannabinoids and short-term and sustained improvement in mental health: a prospective observational study of meditators. Evid. Based Complement. Alternat. Med. 2020:8438272. 10.1155/2020/8438272 [PMC free article] [PubMed] [CrossRef[]
  • Saeed S. A., Cunningham K., Bloch R. M. (2019). Depression and anxiety disorders: benefits of exercise, yoga, and meditation. Am. Fam. Physician 99 620–627. [PubMed[]
  • Sagar K. A., Dahlgren M. K., Lambros A. M., Smith R. T., El-Abboud C., Gruber S. A. (2021). An observational, longitudinal study of cognition in medical cannabis patients over the course of 12 months of treatment: preliminary results. J. Int. Neuropsychol. Soc. 27 648–660. 10.1017/S1355617721000114 [PubMed] [CrossRef[]
  • Sam A. H., Salem V., Ghatei M. A. (2011). Rimonabant: from RIO to Ban. J. Obes. 2011:432607. 10.1155/2011/432607 [PMC free article] [PubMed] [CrossRef[]
  • Santos N. A., Martins N. M., Sisti F. M., Fernandes L. S., Ferreira R. S., Queiroz R. H., et al. (2015). The neuroprotection of cannabidiol against MPP?-induced toxicity in PC12 cells involves trkA receptors, upregulation of axonal and synaptic proteins, neuritogenesis, and might be relevant to Parkinson’s disease. Toxicol. In Vitro 30(1 Pt B) 231–240. 10.1016/j.tiv.2015.11.004 [PubMed] [CrossRef[]
  • Sarzani R., Bordicchia M., Marcucci P., Bedetta S., Santini S., Giovagnoli A., et al. (2009). Altered pattern of cannabinoid type 1 receptor expression in adipose tissue of dysmetabolic and overweight patients. Metabolism 58 361–367. 10.1016/j.metabol.2008.10.009 [PubMed] [CrossRef[]
  • Scherma M., Dessi C., Muntoni A. L., Lecca S., Satta V., Luchicchi A., et al. (2016). Adolescent delta(9)-tetrahydrocannabinol exposure alters WIN55,212-2 self-administration in adult rats. Neuropsychopharmacology 41 1416–1426. 10.1038/npp.2015.295 [PMC free article] [PubMed] [CrossRef[]
  • Schonke M., Martinez-Tellez B., Rensen P. C. (2020). Role of the endocannabinoid system in the regulation of the skeletal muscle response to exercise. Curr. Opin. Pharmacol. 52 52–60. 10.1016/j.coph.2020.05.003 [PubMed] [CrossRef[]
  • Schuchman E. H., Ledesma M. D., Simonaro C. M. (2021). New paradigms for the treatment of lysosomal storage diseases: targeting the endocannabinoid system as a therapeutic strategy. Orphanet J. Rare Dis. 16:151. 10.1186/s13023-021-01779-4 [PMC free article] [PubMed] [CrossRef[]
  • Schwartz R. H., Gruenewald P. J., Klitzner M., Fedio P. (1989). Short-term memory impairment in cannabis-dependent adolescents. Am. J. Dis. Child 143 1214–1219. 10.1001/archpedi.1989.02150220110030 [PubMed] [CrossRef[]
  • Scotter E. L., Abood M. E., Glass M. (2010). The endocannabinoid system as a target for the treatment of neurodegenerative disease. Br. J. Pharmacol. 160 480–498. [PMC free article] [PubMed[]
  • Scuderi C., Bronzuoli M. R., Facchinetti R., Pace L., Ferraro L., Broad K. D., et al. (2018). Ultramicronized palmitoylethanolamide rescues learning and memory impairments in a triple transgenic mouse model of Alzheimer’s disease by exerting anti-inflammatory and neuroprotective effects. Transl. Psychiatry 8:32. 10.1038/s41398-017-0076-4 [PMC free article] [PubMed] [CrossRef[]
  • Selkoe D. J. (2011). Alzheimer’s disease. Cold Spring Harb. Perspect. Biol. 3:a004457[PMC free article] [PubMed[]
  • Sharma C., Sadek B., Goyal S. N., Sinha S., Kamal M. A., Ojha S. (2015). Small molecules from nature targeting G-protein coupled cannabinoid receptors: potential leads for drug discovery and development. Evid. Based Complement. Alternat. Med. 2015:238482. 10.1155/2015/238482 [PMC free article] [PubMed] [CrossRef[]
  • Sharon H., Maron-Katz A., Ben Simon E., Flusser Y., Hendler T., Tarrasch R., et al. (2016). Mindfulness meditation modulates pain through endogenous opioids. Am. J. Med. 129 755–758. [PubMed[]
  • Shelef A., Barak Y., Berger U., Paleacu D., Tadger S., Plopsky I., et al. (2016). Safety and efficacy of medical cannabis oil for behavioral and psychological symptoms of dementia: an-open label, add-on, pilot study. J. Alzheimers Dis. 51 15–19. 10.3233/JAD-150915 [PubMed] [CrossRef[]
  • Shohet A., Khlebtovsky A., Roizen N., Roditi Y., Djaldetti R. (2017). Effect of medical cannabis on thermal quantitative measurements of pain in patients with Parkinson’s disease. Eur. J. Pain 21 486–493. 10.1002/ejp.942 [PubMed] [CrossRef[]
  • Sidibeh C. O., Pereira M. J., Lau Borjesson J., Kamble P. G., Skrtic S., Katsogiannos P., et al. (2017). Role of cannabinoid receptor 1 in human adipose tissue for lipolysis regulation and insulin resistance. Endocrine 55 839–852. [PMC free article] [PubMed[]
  • Sierra A. Y., Gratacós E., Carrasco P., Clotet J., Ureña J., Serra D., et al. (2008). CPT1c is localized in endoplasmic reticulum of neurons and has carnitine palmitoyltransferase activity. J. Biol. Chem. 283 6878–6885. [PubMed[]
  • Sim M. S., Hatim A., Reynolds G. P., Mohamed Z. (2013). Association of a functional FAAH polymorphism with methamphetamine-induced symptoms and dependence in a Malaysian population. Pharmacogenomics 14 505–514. 10.2217/pgs.13.25 [PubMed] [CrossRef[]
  • Simopoulos A. P. (2016). An increase in the omega-6/omega-3 fatty acid ratio increases the risk for obesity. Nutrients 8:128[PMC free article] [PubMed[]
  • Simopoulos A. P. (2020). Omega-6 and omega-3 fatty acids: endocannabinoids, genetics and obesity?. OCL 27:7[]
  • Sipe J. C., Chiang K., Gerber A. L., Beutler E., Cravatt B. F. (2002). A missense mutation in human fatty acid amide hydrolase associated with problem drug use. Proc. Natl. Acad. Sci. U.S.A. 99 8394–8399. [PMC free article] [PubMed[]
  • Soares P. N., Miranda R. A., Peixoto T. C., Caramez F. A. H., Guarda D. S., Manhaes A. C., et al. (2019). Cigarette smoke during lactation in rat female progeny: late effects on endocannabinoid and dopaminergic systems. Life Sci. 232:116575. 10.1016/j.lfs.2019.116575 [PubMed] [CrossRef[]
  • Solowij N., Michie P. T. (2007). Cannabis and cognitive dysfunction: parallels with endophenotypes of schizophrenia? J. Psychiatry Neurosci. 32 30–52. [PMC free article] [PubMed[]
  • Soya H., Nakamura T., Deocaris C. C., Kimpara A., Iimura M., Fujikawa T., et al. (2007). BDNF induction with mild exercise in the rat hippocampus. Biochem. Biophys. Res. Commun. 358 961–967. [PubMed[]
  • Stang J., Huffman L. G. (2016). Position of the academy of nutrition and dietetics: obesity, reproduction, and pregnancy outcomes. J. Acad. Nutr. Diet 116 677–691. 10.1016/j.jand.2016.01.008 [PubMed] [CrossRef[]
  • Stark T., Di Bartolomeo M., Di Marco R., Drazanova E., Platania C. B. M., Iannotti F. A., et al. (2020). Altered dopamine D3 receptor gene expression in MAM model of schizophrenia is reversed by peripubertal cannabidiol treatment. Biochem. Pharmacol. 177:114004. 10.1016/j.bcp.2020.114004 [PubMed] [CrossRef[]
  • Stark T., Ruda-Kucerova J., Iannotti F. A., D’addario C., Di Marco R., Pekarik V., et al. (2019). Peripubertal cannabidiol treatment rescues behavioral and neurochemical abnormalities in the MAM model of schizophrenia. Neuropharmacology 146 212–221. 10.1016/j.neuropharm.2018.11.035 [PubMed] [CrossRef[]
  • Stringer R. L., Laufer B. I., Kleiber M. L., Singh S. M. (2013). Reduced expression of brain cannabinoid receptor 1 (Cnr1) is coupled with an increased complementary micro-RNA (miR-26b) in a mouse model of fetal alcohol spectrum disorders. Clin. Epigenetics 5:14. 10.1186/1868-7083-5-14 [PMC free article] [PubMed] [CrossRef[]
  • Stringfield S. J., Torregrossa M. M. (2021). Intravenous self-administration of delta-9-THC in adolescent rats produces long-lasting alterations in behavior and receptor protein expression. Psychopharmacology 238 305–319. 10.1007/s00213-020-05684-9 [PMC free article] [PubMed] [CrossRef[]
  • Styrczewska M., Kulma A., Ratajczak K., Amarowicz R., Szopa J. (2012). Cannabinoid-like anti-inflammatory compounds from flax fiber. Cell. Mol. Biol. Lett. 17 479–499. 10.2478/s11658-012-0023-6 [PMC free article] [PubMed] [CrossRef[]
  • Suijun W., Zhen Y., Ying G., Yanfang W. (2014). A role for trans-caryophyllene in the moderation of insulin secretion. Biochem. Biophys. Res. Commun. 444 451–454. 10.1016/j.bbrc.2013.11.136 [PubMed] [CrossRef[]
  • Szutorisz H., Hurd Y. L. (2016). Epigenetic effects of cannabis exposure. Biol. Psychiatry 79 586–594. [PMC free article] [PubMed[]
  • Tagliamonte S., Laiola M., Ferracane R., Vitale M., Gallo M. A., Meslier V., et al. (2021). Mediterranean diet consumption affects the endocannabinoid system in overweight and obese subjects: possible links with gut microbiome, insulin resistance and inflammation. Eur. J. Nutr. 60 3703–3716. 10.1007/s00394-021-02538-8 [PMC free article] [PubMed] [CrossRef[]
  • Tao R., Li C., Jaffe A. E., Shin J. H., Deep-Soboslay A., Yamin R., et al. (2020). Cannabinoid receptor CNR1 expression and DNA methylation in human prefrontal cortex, hippocampus and caudate in brain development and schizophrenia. Transl. Psychiatry 10:158. 10.1038/s41398-020-0832-8 [PMC free article] [PubMed] [CrossRef[]
  • Terzian A. L., Drago F., Wotjak C. T., Micale V. (2011). The dopamine and cannabinoid interaction in the modulation of emotions and cognition: assessing the role of cannabinoid CB1 receptor in neurons expressing dopamine D1 receptors. Front. Behav. Neurosci. 5:49. 10.3389/fnbeh.2011.00049 [PMC free article] [PubMed] [CrossRef[]
  • Terzian A. L., Micale V., Wotjak C. T. (2014). Cannabinoid receptor type 1 receptors on GABAergic vs. Glutamatergic neurons differentially gate sex-dependent social interest in mice. Eur. J. Neurosci. 40 2293–2298. 10.1111/ejn.12561 [PubMed] [CrossRef[]
  • Thanos P. K., Ramalhete R. C., Michaelides M., Piyis Y. K., Wang G. J., Volkow N. D. (2008). Leptin receptor deficiency is associated with upregulation of cannabinoid 1 receptors in limbic brain regions. Synapse 62 637–642. 10.1002/syn.20531 [PMC free article] [PubMed] [CrossRef[]
  • Thomazeau A., Bosch-Bouju C., Manzoni O., Layé S. (2017). Nutritional n-3 PUFA deficiency abolishes endocannabinoid gating of hippocampal long-term potentiation. Cereb. Cortex 27 2571–2579. 10.1093/cercor/bhw052 [PubMed] [CrossRef[]
  • Thornton C., Hagberg H. (2015). Role of mitochondria in apoptotic and necroptotic cell death in the developing brain. Clin. Chim. Acta 451 35–38. 10.1016/j.cca.2015.01.026 [PMC free article] [PubMed] [CrossRef[]
  • Thorsdottir I., Tomasson H., Gunnarsdottir I., Gisladottir E., Kiely M., Parra M. D., et al. (2007). Randomized trial of weight-loss-diets for young adults varying in fish and fish oil content. Int. J. Obes. 31 1560–1566. [PubMed[]
  • Toniolo E. F., Maique E. T., Ferreira W. A., Jr., Heimann A. S., Ferro E. S., Ramos-Ortolaza D. L., et al. (2014). Hemopressin, an inverse agonist of cannabinoid receptors, inhibits neuropathic pain in rats. Peptides 56 125–131. 10.1016/j.peptides.2014.03.016 [PMC free article] [PubMed] [CrossRef[]
  • Toth M. J., Tchernof A., Sites C. K., Poehlman E. T. (2000). Effect of menopausal status on body composition and abdominal fat distribution. Int. J. Obes. Relat. Metab. Disord. 24 226–231. [PubMed[]
  • Tremblay B. L., Guenard F., Rudkowska I., Lemieux S., Couture P., Vohl M. C. (2017). Epigenetic changes in blood leukocytes following an omega-3 fatty acid supplementation. Clin. Epigenetics 9:43[PMC free article] [PubMed[]
  • Tripathi R. K. P. (2020). A perspective review on fatty acid amide hydrolase (FAAH) inhibitors as potential therapeutic agents. Eur. J. Med. Chem. 188:111953. 10.1016/j.ejmech.2019.111953 [PubMed] [CrossRef[]
  • Tsuboi H., Sakakibara H., Matsunaga M., Tatsumi A., Yamakawa-Kobayashi K., Yoshida N., et al. (2020). Omega-3 eicosapentaenoic acid is related to happiness and a sense of fulfillment-a study among female nursing workers. Nutrients 12:3462. 10.3390/nu12113462 [PMC free article] [PubMed] [CrossRef[]
  • Tsuyama S., Oikawa D., Tsuji Y., Akimoto Y., Jikuya H., Furuse M. (2009). Dietary conjugated linoleic acid modifies the brain endocannabinoid system in mice. Nutr. Neurosci. 12 155–159. 10.1179/147683009X423373 [PubMed] [CrossRef[]
  • Tysnes O. B., Storstein A. (2017). Epidemiology of Parkinson’s disease. J. Neural Transm. 124 901–905. [PubMed[]
  • Ueda Y., Miyagawa N., Wakitani K. (2007). Involvement of cannabinoid CB2 receptors in the IgE-mediated triphasic cutaneous reaction in mice. Life Sci. 80 414–419. 10.1016/j.lfs.2006.09.026 [PubMed] [CrossRef[]
  • van den Elsen G. A., Ahmed A. I., Verkes R. J., Kramers C., Feuth T., Rosenberg P. B., et al. (2015). Tetrahydrocannabinol for neuropsychiatric symptoms in dementia: a randomized controlled trial. Neurology 84 2338–2346. [PMC free article] [PubMed[]
  • van der Stelt M., Mazzola C., Esposito G., Matias I., Petrosino S., De Filippis D., et al. (2006). Endocannabinoids and beta-amyloid-induced neurotoxicity in vivo: effect of pharmacological elevation of endocannabinoid levels. Cell. Mol. Life Sci. 63 1410–1424. 10.1007/s00018-006-6037-3 [PubMed] [CrossRef[]
  • van Eyk H. J., Van Schinkel L. D., Kantae V., Dronkers C. E. A., Westenberg J. J. M., De Roos A., et al. (2018). Caloric restriction lowers endocannabinoid tonus and improves cardiac function in type 2 diabetes. Nutr. Diabetes 8:6. 10.1038/s41387-017-0016-7 [PMC free article] [PubMed] [CrossRef[]
  • Van Gaal L., Pi-Sunyer X., Despres J. P., Mccarthy C., Scheen A. (2008). Efficacy and safety of rimonabant for improvement of multiple cardiometabolic risk factors in overweight/obese patients: pooled 1-year data from the Rimonabant in Obesity (RIO) program. Diabetes Care 31 Suppl. 2 S229–S240. 10.2337/dc08-s258 [PubMed] [CrossRef[]
  • van Rooden E. J., Van Esbroeck A. C. M., Baggelaar M. P., Deng H., Florea B. I., Marques A. R. A., et al. (2018). Chemical proteomic analysis of serine hydrolase activity in niemann-pick type C mouse brain. Front. Neurosci. 12:440. 10.3389/fnins.2018.00440 [PMC free article] [PubMed] [CrossRef[]
  • Vanier M. T. (2010). Niemann-Pick disease type C. Orphanet J. Rare Dis. 5:16[PMC free article] [PubMed[]
  • Velayudhan L., Van Diepen E., Marudkar M., Hands O., Suribhatla S., Prettyman R., et al. (2014). Therapeutic potential of cannabinoids in neurodegenerative disorders: a selective review. Curr. Pharm. Des. 20 2218–2230. [PubMed[]
  • Velusami C. C., Agarwal A., Mookambeswaran V. (2013). Effect of Nelumbo nucifera petal extracts on lipase, adipogenesis, adipolysis, and central receptors of obesity. Evid. Based Complement. Alternat. Med. 2013:145925. 10.1155/2013/145925 [PMC free article] [PubMed] [CrossRef[]
  • Verty A. N., Stefanidis A., Mcainch A. J., Hryciw D. H., Oldfield B. (2015). Anti-obesity effect of the CB2 receptor agonist JWH-015 in diet-induced obese mice. PLoS One 10:e0140592. 10.1371/journal.pone.0140592 [PMC free article] [PubMed] [CrossRef[]
  • Volkow N. D., Baler R. D., Compton W. M., Weiss S. R. (2014). Adverse health effects of marijuana use. N. Engl. J. Med. 370 2219–2227. [PMC free article] [PubMed[]
  • Vučković S., Srebro D., Vujović K. S., Vučetić Č, Prostran M. (2018). Cannabinoids and pain: new insights from old molecules. Front. Pharmacol. 9:1259. 10.3389/fphar.2018.01259 [PMC free article] [PubMed] [CrossRef[]
  • Wade M. R., Degroot A., Nomikos G. G. (2006). Cannabinoid CB1 receptor antagonism modulates plasma corticosterone in rodents. Eur. J. Pharmacol. 551 162–167. [PubMed[]
  • Wajner M. (2019). Neurological manifestations of organic acidurias. Nat. Rev. Neurol. 15 253–271. [PubMed[]
  • Walsh S., Mnich K., Mackie K., Gorman A. M., Finn D. P., Dowd E. (2010). Loss of cannabinoid CB1 receptor expression in the 6-hydroxydopamine-induced nigrostriatal terminal lesion model of Parkinson’s disease in the rat. Brain Res. Bull. 81 543–548. 10.1016/j.brainresbull.2010.01.009 [PMC free article] [PubMed] [CrossRef[]
  • Wang Y., Yu T., Zhou Y., Wang S., Zhou X., Wang L., et al. (2020). Carnitine palmitoyltransferase 1C contributes to progressive cellular senescence. Aging 12 6733–6755. 10.18632/aging.103033 [PMC free article] [PubMed] [CrossRef[]
  • Warburton D. E. R., Nicol C. W., Bredin S. S. D. (2006). Health benefits of physical activity: the evidence. CMAJ 174 801–809. [PMC free article] [PubMed[]
  • Ware M. A., Jensen D., Barrette A., Vernec A., Derman W. (2018). Cannabis and the health and performance of the elite athlete. Clin. J. Sport Med. 28 480–484. [PMC free article] [PubMed[]
  • Wellman M., Abizaid A. (2015). Growth hormone secretagogue receptor dimers: a new pharmacological target. eNeuro 2:ENEURO.0053-14.2015. 10.1523/ENEURO.0053-14.2015 [PMC free article] [PubMed] [CrossRef[]
  • Whiting P. F., Wolff R. F., Deshpande S., Di Nisio M., Duffy S., Hernandez A. V., et al. (2015). Cannabinoids for medical use: a systematic review and meta-analysis. JAMA 313 2456–2473. [PubMed[]
  • Widmer R. J., Flammer A. J., Lerman L. O., Lerman A. (2015). The Mediterranean diet, its components, and cardiovascular disease. Am. J. Med. 128 229–238. [PMC free article] [PubMed[]
  • Wirdefeldt K., Adami H. O., Cole P., Trichopoulos D., Mandel J. (2011). Epidemiology and etiology of Parkinson’s disease: a review of the evidence. Eur. J. Epidemiol. 26 Suppl. 1 S1–S58. [PubMed[]
  • Wolfgang M. J., Kurama T., Dai Y., Suwa A., Asaumi M., Matsumoto S., et al. (2006). The brain-specific carnitine palmitoyltransferase-1c regulates energy homeostasis. Proc. Natl. Acad. Sci. U.S.A. 103 7282–7287. [PMC free article] [PubMed[]
  • Woodyard C. (2011). Exploring the therapeutic effects of yoga and its ability to increase quality of life. Int. J. Yoga 4 49–54. 10.4103/0973-6131.85485 [PMC free article] [PubMed] [CrossRef[]
  • World Health Organization (2015). World Report on Ageing and Health. Geneva: World Health Organization. []
  • Wrann C. D., White J. P., Salogiannnis J., Laznik-Bogoslavski D., Wu J., Ma D., et al. (2013). Exercise induces hippocampal BDNF through a PGC-1α/FNDC5 pathway. Cell Metab. 18 649–659. [PMC free article] [PubMed[]
  • Xapelli S., Agasse F., Grade S., Bernardino L., Ribeiro F. F., Schitine C. S., et al. (2014). Modulation of subventricular zone oligodendrogenesis: a role for hemopressin? Front. Cell. Neurosci. 8:59. 10.3389/fncel.2014.00059 [PMC free article] [PubMed] [CrossRef[]
  • Xapelli S., Agasse F., Sarda-Arroyo L., Bernardino L., Santos T., Ribeiro F. F., et al. (2013). Activation of type 1 cannabinoid receptor (CB1R) promotes neurogenesis in murine subventricular zone cell cultures. PLoS One 8:e63529. 10.1371/journal.pone.0063529 [PMC free article] [PubMed] [CrossRef[]
  • Ye Y., Abu El Haija M., Morgan D. A., Guo D., Song Y., Frank A., et al. (2020). Endocannabinoid receptor-1 and sympathetic nervous system mediate the beneficial metabolic effects of gastric bypass. Cell Rep. 33:108270. 10.1016/j.celrep.2020.108270 [PMC free article] [PubMed] [CrossRef[]
  • Zhang X., Zong B., Zhao W., Li L. (2021). Effects of mind-body exercise on brain structure and function: a systematic review on MRI studies. Brain Sci. 11:205[PMC free article] [PubMed[]
  • Zhang Z., Guo Y., Zhang S., Zhang Y., Wang Y., Ni W., et al. (2013). Curcumin modulates cannabinoid receptors in liver fibrosis in vivo and inhibits extracellular matrix expression in hepatic stellate cells by suppressing cannabinoid receptor type-1 in vitro. Eur. J. Pharmacol. 721 133–140. 10.1016/j.ejphar.2013.09.042 [PubMed] [CrossRef[]
  • Zhao J., Wang M., Liu W., Ma Z., Wu J. (2020). Activation of cannabinoid receptor 2 protects rat hippocampal neurons against Aβ-induced neuronal toxicity. Neurosci. Lett. 735:135207. 10.1016/j.neulet.2020.135207 [PubMed] [CrossRef[]
  • Zolotov Y., Gruber S. A. (2021). Cannabis and aging: research remains in its infancy. Am. J. Drug Alcohol Abuse 47 523–526. 10.1080/00952990.2021.1949334 [PubMed] [CrossRef[]
  • Zuardi A. W., Crippa J. A., Hallak J. E., Pinto J. P., Chagas M. H., Rodrigues G. G., et al. (2009). Cannabidiol for the treatment of psychosis in Parkinson’s disease. J. Psychopharmacol. 23 979–983. [PubMed[]

Articles from Frontiers in Neuroscience are provided here courtesy of Frontiers Media SA

Leave a Reply

en English
X